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ABSTRACT
Effects of High Dose Chemotherapy on the Bone Marrow
Microenvironment
Brett M. Hall
The bone marrow microenvironment composed in part of stromal cells provides
the niche in which normal hematopoiesis occurs. Hematopoiesis generates cellular
components of the immune system and blood through proliferation and differentiation of
multipotent hematopoietic stem cells (HSC).
In preparation for bone marrow
transplantation, radiation or chemotherapy treatment temporarily disrupts the balance of
hematopoiesis as many HSC and progenitor cells are destroyed. Following treatment
cessation, transplanted HSC and progenitor cells migrate, or “home”, back to the bone
marrow microenvironment and initiate productive hematopoiesis. While the mechanism
of bone marrow homing is not completely understood, several soluble factors and
adhesion molecules are known to have specific roles in the process. The chemokine
stromal derived factor-1 (SDF-1) and the adhesion molecule vascular cell adhesion
molecule-1 (VCAM-1) are critical in mediating HSC chemotaxis and adhesion,
respectively. In addition, both molecules have been demonstrated to be critical for
maintenance of productive hematopoiesis.
We previously demonstrated and characterized stromal cell VCAM-1 protein
down-regulation following in vitro exposure to the topoisomerase II inhibitor etoposide
(VP-16). VP-16-induced VCAM-1 down-regulation is associated with an impairment of
stromal cell layers to support early lymphoid and myeloid cell proliferation. More
recently, we evaluated stromal cell SDF-1 protein production following exposure to
several chemotherapeutic drugs, and we found that bone marrow stromal cell SDF-1
protein secretion is also disrupted following VP-16 or doxorubicin exposure. SDF-1
protein reductions correlated with a reduced capacity of B-cell progenitor lines to
migrate toward chemotherapy-treated stromal cell layers. Finally, we have generated
and characterized murine stromal cell lines that constitutively express human VCAM-1
protein. Human VCAM-1 expression is maintained following exposure to VP-16 and
overall elevation of VCAM-1 protein offset diminished viabilities in B cell progenitors
following removal of exogenous IL-7.
This research will contribute to better understanding mechanistic models that
address the hypothesis that aggressive chemotherapy disrupts immune system
reconstitution through bone marrow microenvironment damage and disruption of
molecules that regulate homing. Ultimately, this work may improve our understanding of
delayed immune system recovery following aggressive chemotherapy and lead to
enhanced cancer treatment strategies.
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CHAPTER I

Introduction and Review of Literature
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I.

Introduction and Significance

Hematopoiesis is the production of blood cells through stem cell renewal,
proliferation and differentiation (1;2). In postnatal mammals, hematopoiesis occurs in
the extravascular spaces of red as “hematopoietic” bone marrow (3;4).

Unique

biological compositions of individual bone marrow microenvironments predictably favor
B-lymphopoiesis, erythropoiesis, or granulopoiesis. Hematopoietic microenvironments
are composed of extracellular matrix (ECM), growth factors, and supportive
hematopoietic and non-hematopoietic cells (5-7).
Fibroblastic stromal cells (stromal cell) are best characterized as principle
microenvironmental regulators of B-lymphopoiesis (8-16). Soluble chemokine stromal
derived factor-1 (SDF-1) and surface adhesion molecule vascular cell adhesion
molecule-1 (VCAM-1) are two of the key factors produced by stromal cells that influence
B cell development. SDF-1 is essential for establishing bone marrow concentration
gradients that aid in the retention and attraction of hematopoietic progenitor and stem
cells to the bone marrow, as well as influencing the expansion of immature B-cells
(17;18). VCAM-1 is a critical stromal cell adhesion molecule that maintains the viability
of stem cells, retains hematopoietic stem and progenitor cells within the bone marrow,
and supports productive B-lymphopoiesis (12;19-22).
Sustained dysregulation of either of these stromal cell proteins would have
devastating effects on the capacity of the bone marrow to adequately support steady
state B-lymphopoiesis or to restore B-lymphopoiesis following bone marrow
transplantation. Delays in B-cell recovery following ablative chemo-radiotherapy and
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bone marrow transplantation are observed clinically, and at times, observed B-cell
deficits do not respond to exogenous growth factor therapy, suggesting potential
damage to the supportive bone marrow microenvironments that support Blymphopoiesis (23-27).
Bone marrow transplantation is a common treatment strategy for many advanced
stages of metastatic cancer (28-31).

As such, defining the impact of high dose

chemotherapy on bone marrow stromal cell function, with particular focus on key
regulatory factors such as VCAM-1 and SDF-1, is essential. These studies may better
define

our

understanding

of

hematopoietic

recovery

following

bone

marrow

transplantation and also to the development of intervention strategies that enhance Bcell recovery. Data in this dissertation may contribute to optimized chemotherapeutic
treatments that may enhance bone marrow capacity to restore and maintain robust
hematopoiesis following bone marrow transplantation.
II.

Hematopoiesis
Hematopoietic development in mammals involves progressive maturation from

early or primitive hematopoiesis to definitive postnatal hematopoiesis at birth (Figure 1)
(32-35). Primitive hematopoiesis, as found in the yolk sac (YS), does not contribute to
later stages of hematopoiesis including establishment of fetal liver hematopoiesis. In
contrast, definitive hematopoiesis expands to other hematopoietic tissues in a
coordinated movement observed sequentially at distinct anatomical locations during
embryogenesis (Figure 1).

Mammalian hematopoietic stem cells originate from the

ventral mesoderm cell layer (32;34). The more dorsal regions of the mesoderm give
rise to stem cells for mesenchyme, kidney, muscle, and notochord (32).

3

Primitive

Mammalian Hematopoietic System Development

Fertilization

Birth

Prenatal
Hematopoiesis

AGM

Spleen

FL

Postnatal
Hematopoiesis

BM

Intraembryonic

YS
Extraembryonic

Figure 1. Anatomical locations of mammalian hematopoietic system during ontogeny
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hematopoiesis is first observed in the extraembryonic yolk sac and the intraembryonic
AGM region (Aorta, Gonad, Mesonephros) (36-38). Embryonic vascularization allows
for subsequent migration of primitive hematopoietic cells and colonization of sequential
fetal tissues including the fetal liver, spleen and bone marrow (Figure 1) (39). Around
birth, hematopoiesis predominantly shifts to the bone marrow (40;41).
Most mature blood cells have definitively short life spans (42-45). Therefore,
hematopoiesis is a highly active process that is required to maintain blood cell numbers
even during normal physiological states.

Trilineage hematopoiesis (lymphopoiesis,

myelopoiesis, and erythropoiesis) is regulated through environmental cues that act on
primitive hematopoietic stem cells (HSC).

Primitive hematopoietic stem cells are

defined as a population of pluripotent cells that are able to self-renew and differentiate
along each blood cell lineage (2;35;45;46). These stem cell characteristics can be
determined through the use of multiple in vitro and in vivo assays described in detail
elsewhere (47-49).

As HSC differentiate, they become more committed to specific

lineages and their capacity for self-renewal is diminished. Various stages of maturing
HSC’s are collectively referred to as hematopoietic progenitor cells (HPC). HPC have
limited self-renewing capacities and are committed to either the lymphoid or myeloid
lineages (50-54). Following bone marrow transplantation in humans, or experimentally
in animals, the HSC and HPC populations contribute to long-term and short-term
hematopoietic reconstitution respectively (55-57).
Further differentiation and maturation of HPC lead to lineage specific expansion
and maintenance of the three blood cell lineages. The common lymphoid progenitor
cell (CLP) is the most immature lymphoid cell committed to the B or T-cell
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developmental pathway.

Phenotypic characterization of the CLP revealed that

coexpression of CD34 and CXCR-4 represents the most immature CLP (i.e. precedes
terminal deoxynucleotidyl transferase (TdT) and IL-7 receptor expression) (58). Even at
this early progenitor cell stage, stromal cell influence, via SDF-1 production, is
suggested from previous work that demonstrated that CXCR-4 activation induces
myelosuppression (59). Regulation of stromal cell-dependent B-lymphopoiesis is central
to work described in this thesis, and further discussion of hematopoiesis is focused on
stromal cell regulation of B-cell development within the bone marrow. Detailed reviews
on myeloid and erythroid cell development have been previously published (54;60-62).
Several groups have separately classified the stages of B-cell development
based on germline DNA changes associated with B-cell receptor maturation, phenotypic
expression of various proteins within the cytoplasm or on the cell membrane, growth
factor and stromal cell dependence, or functional characteristics (63-67). For clarity,
nomenclature for the stages of B-cell maturation in the current discussion corresponds
to the phenotypic characteristics various surface cellular proteins as evaluated by flow
cytometry (Figure 2) (63).
Development of B-lineage cells is tightly regulated by a complex interplay of
soluble factors and adhesion molecules within microenvironmental niches (4;21;68-70).
A primary source of regulatory signals in the marrow microenvironment is bone marrow
stromal cells.

Bone marrow stromal cells produce proliferative, inhibitory, and

chemotactic cytokines (e.g. IL-7, LIF, SCF, GM-CSF, IGF-1, Flt-3 ligand, MIP-1α, and
SDF-1) that act on early hematopoietic progenitor cells. These factors function as either
soluble or stromal anchored glycoproteins (12;71-75).
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Bone marrow stromal cells also produce soluble and membrane anchored matrix
proteins including collagen, fibronectin, and laminin that form a structural niche for
productive hematopoiesis. Importantly, stromal cells express several types of cellular
adhesion molecules including VCAM-1, fibronectin, and hyaluranate that have been
shown to influence hematopoiesis (76-78).

The necessity of physical interactions

between stromal cells and developing B-cells through VCAM-1 and VLA-4 has been
well characterized (76;79-84).
Cell surface expression of VCAM-1 was first identified on human umbilical vein
endothelial cells following exposure to inflammatory cytokines (85;86). VCAM-1 was
later identified as a cell surface adhesion molecule with the capacity to promote
adherence of many cell types including basophils, eosinophils, neutrophils, monocytes,
lymphocytes, CD34+ hematopoietic cells, and early B-lineage cells (79;82;83;87-91).
Structural characterization identified VCAM-1 as a membrane anchored glycoprotein
consisting of a 19 amino acid cytoplasmic tail and seven Ig-like extracellular domains
(85;92;93). Mice express an alternative form of VCAM-1 that is composed of the first
three amino terminal immunoglobulin(Ig)-like domains bound to the cell membrane
using a glycol phospatidylinositol (GPI) anchor (94;95) (Figure 3).
VCAM-1’s primary ligand is α4β1 (VLA-4), which is predominantly expressed on
stem cells and most lymphoid lineage cells. Several groups have demonstrated that
blocking antibodies to VCAM-1 on stromal cells or VLA-4 on hematopoietic progenitor
cells in vitro and in vivo inhibited B-lymphopoiesis and resulted in subsequent induction
of apoptosis in CD34+ hematopoietic cells (79-83;89;91;96-98). Further support for the
role of VLA-4 in B-lymphopoiesis was demonstrated by comparing α4-/- (VLA-4 – α4β1)
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or α5-/- (VLA-5 – α5β1): RAG-2-/- chimeric mice to wild type: RAG-2-/- chimeric control
mice (84). The α4-/- (VLA-4 – α4β1): RAG-2-/- chimeric mice have both α4-/- RAG-2+/+
and α4+/+ RAG-2-/- hematopoietic stem cells. It had been previously demonstrated that
loss of RAG-2 expression results in a stringent block from the pro-B to pre-B transition
in B-lymphopoiesis (99).

Therefore, only the genetically manipulated RAG-2+/+

hematopoietic cells have the capacity to restore lymphopoiesis in RAG-2-/- mice. While
α4-/- chimeric mice failed to develop more mature bone marrow B-cells (B220+IgM+), the
α5-/- and the wild type control chimeric mice had normal restoration of bone marrow Blymphopoiesis (84).
Functional analysis of VCAM-1-/- knockout mice is not possible as these mice die
during embryogenesis (100). Recently however, VCAM-1 conditional knockouts were
generated and characterized (101). These mice had reduced immature and mature B
cell numbers in the bone marrow, further demonstrating the requirement for VCAM-1 in
B cell development (101). In addition, the same group established a definitive role for
VCAM-1 in bone marrow lymphocyte homing, which will be discussed in further detail in
section V.
III.

Bone Marrow Anatomy
Hematopoietic bone marrow is an extensively vascularized organ system. In

fact, all hematopoietic tissues (e.g. yolk sac, AGM region, fetal liver, spleen, and bone
marrow) and those that will support hematopoiesis (e.g. kidney), provided the correct
microenvironment, are extensively vascularized (102;103). Yellow “fatty” bone marrow
receives only one-third the blood flow as compared to red “hematopoietic” marrow
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(104). These observations suggest that a complex vascular network and regulated
blood flow are necessary, but not adequate, for productive hematopoiesis.
Bone marrow represents 1-2.5% of total body mass in humans. Of the total
marrow, 25-75% is red “active hematopoietic” marrow versus yellow “fatty and nonhematopoietically active marrow”.

“Active hematopoietic” marrow receives 2-4% of

cardiac output under normal physiological conditions (105-107). Unlike most organs,
the bone marrow is unique as it is encased in non-flexible bone. This restricted isolation
further enhances the dependence on vascular support for homeostasis of its
physiological functions.

Blood flow to and from the bone marrow must be tightly

regulated in order to maintain hematopoietic cell egress, cytokine release, O2/CO2
exchange, cellular bone marrow homing, osmotic pressure, and nutrient/waste
exchange.
Alterations in hematopoietic activity are typically associated with corresponding
changes in bone marrow blood flow. A classic technique that enhances bone marrow
erythropoiesis is the induction of anemia in animals through controlled blood loss (108).
In animals with induced anemia, increased bone marrow erythropoiesis was
accompanied by a corresponding increase in bone marrow blood flow by up to 3-fold
(109-111).

However, the bone marrow maintains similar blood flow and vascular

resistance, as compared to severe changes seen in muscle tissues, associated with
overall increases in arterial pressure and increased heart rate during moderate exercise
(104).

Hypovolaemia

(reduced

arterial

blood

pressure)

induces

immediate

vasoconstriction in many organs to offset the reduced total arterial pressure (112). A
50% reduction of arterial blood pressure in dogs results in a five-fold reduction in bone
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marrow blood flow suggesting increased bone marrow vascular resistance (104).
Finally, increases in bone marrow cellularity associated with several bone-harbored
leukemias result in corresponding bone marrow blood flow increases (107).

While

many of the regulatory mechanisms are yet to be fully defined, these data demonstrate
that the bone marrow vasculature is responsive to various physiological signals.
Regulation of bone marrow blood vessel tone and blood flow are not fully
understood, but several factors are known to influence bone marrow blood vessel
tension that ultimately influence blood flow. Bone marrow blood vessels, composed of
endothelial cells and smooth muscle, are regulated by local cytokine levels, systemic
factors and endothelial derived substances (111-116).

Although the bone marrow

vasculature is innervated, no functional alterations in bone marrow blood flow have
been attributed directly to neuronal activity (111;117).
Hematopoietic bone marrow is a dynamic organ system that can be found
throughout the mammalian skeletal system at various stages of life.

In one study,

Fliedner outlined a model in which peripheral blood stem cells are a transitory stem cell
population (42).

These transitory stem cells represent the peripheral stem cell

population in a steady state exchange and balance of stem cells between all active
hematopoietic bone marrow and the peripheral blood. In this way, mammals are able to
maintain or restore stem cell pools equally between all supportive hematopoietic
microenvironments following injury or under normal physiological states (42).
IV.

Bone Marrow Microenvironment
The term “hemopoietic inductive microenvironment (HIM)” (later shortened to

hematopoietic microenvironment or microenvironment) was first coined to define
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microgeographical areas of the spleen and bone marrow that are capable of supporting
specific hematopoietic colony growth (118).

In this early work, Curry and Trentin

observed that the macroscopic hematopoietic spleen colonies (originally described by
Till and McCulloch (119)) were primarily composed of granulocytic, megakaryocytic and
erythrocytic cells and that these colonies were found in discrete anatomical locations
within the spleen.

Additional microenvironmental specificity is suggested by the

observation that while the spleen favors erythropoietic cell colony growth, the bone
marrow favors granulocytic colony formation (120). While the lung is the first capillary
bed that transplanted hematopoietic stem cells (HSC) encounter following intravenous
injection, hematopoietic colonies are not readily observed in the lungs or other nonhematopoietic organs (119;121). Together these data suggest the existence of specific
“microenvironments” that are unique within and between hematopoietic organs (118).
Further support for hematopoietic microenvironments was demonstrated in
studies by Lord, et al. when they reported a spatial distribution of primitive
hematopoietic progenitor cells (Colony Forming Unit – Spleen (CFUS)) and more
differentiated progenitor cells (Colony Forming Unit – Culture (CFUC)) in murine bone
marrow (122;123). In these studies, CFUS-forming cells favored the marginal region of
the bone marrow (closest to the bone) while the CFUC-forming cells favored a more
axial region (toward the center of the bone marrow cavity).
Bone marrow microenvironments are a complex organization of stroma including
fibroblastic stromal cells, adipocytes, macrophages, and endothelial cells. In addition,
accessory cells in the microenvironment include neurons, T-cells, monocytes, and
differentiating hematopoietic cells.

Finally, additional cell-derived proteins including
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growth factors, ECM, cytokines, chemokines, and neural peptides are located in the
bone marrow spaces (4;70;124). While the exact molecular and cellular compositions
of in vivo bone marrow microenvironments that support B lymphopoiesis, myelopoiesis,
or erythropoiesis are not precisely defined, bone marrow hematopoiesis is a process
regulated through the local and dynamic effects of soluble molecules, extracellular
matrix,

and

cell

to

cell

interactions

that

take

place

within

bone

marrow

microenvironments (7). Bone marrow hematopoietic conditions are difficult to evaluate
in vivo, therefore more simplistic in vitro models and in vivo “knock-out” models have
been used to dissect and evaluate specific mechanisms of hematopoiesis (125).
Bone

marrow

microenvironments

regulate

hematopoiesis

through

the

coordinated activities of several cell types including fibroblastic stromal cells, fat cells,
endothelial cells, and macrophages. Fibroblastic bone marrow stromal cells (referred to
as “stromal cell” in this thesis) have been best characterized as the population that
primarily directs hematopoiesis (71;89;126-130). Stromal cells have the capacity to
support both lymphopoiesis and myelopoiesis in vitro, are able to establish active sites
of hematopoiesis in non-hematopoietic organs, and are essential for bone marrow
hematopoietic recovery following ablative cytotoxic treatment (103;131;132). Stromal
cells regulate hematopoiesis through cell-to-cell adhesion, secretion of extracellular
matrix proteins, and production of secreted and membrane bound cytokines.

The

molecular events by which bone marrow stromal cells specifically direct lymphopoiesis
have

been

defined

through

the

use

of

in

vivo

and

in

vitro

models

(16;19;72;76;79;128;133;134). It has been shown that direct interaction with stromal
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cells is essential in murine and human models for maximal support of immature
lymphoid cells (80-82;90;96;130;135;136).
Vascular cell adhesion molecule-1 (VCAM-1), a surface bound stromal cell
adhesion molecule, is an essential component of stromal cell capacity to support
hematopoietic progenitor cells (82;83;89;91;97;98;137;138). Injection of anti-VCAM-1
antibody into mice disrupts stromal cell: hematopoietic progenitor cell associations
(aggregates) and results in disrupted B-lymphopoiesis (83). In addition, hematopoietic
progenitor cells were mobilized in primates following anti-VLA-4 (α4β1 integrin – VCAM1 ligand) antibody treatment (97). These observations support the essential role of
VCAM-1 in regulation of the development of progenitor cells committed to the B cell
lineage.
Bone marrow stromal cells also influence hematopoiesis through Stromal
Derived Factor-1 (SDF-1)-regulated homing and migration of progenitor cells. SDF-1 is
constitutively expressed by bone marrow stromal cells, and disruption of either SDF-1
protein or its receptor CXCR-4 results in diminished bone marrow hematopoiesis (139141). In addition to its role as a chemotactic factor, SDF-1 was also identified as a preB cell growth factor that induced pre-B cell proliferation (18).
Extracellular matrix (ECM), predominantly derived from stromal cells, not only
provides structural support for hematopoietic microenvironments but also acts to
anchor, directly signal and indirectly signal hematopoietic cells (142-144).

Several

studies have demonstrated that growth factors such as IL-3, SCF, GM-CSF, and SDF-1
are able to bind to ECM in a “biologically active” fashion (145-147). In addition, the
bone marrow ECM is involved in coordinating cellular interactions between bone

15

marrow stromal cells and hematopoietic cells (144). However, it appears that the main
function of the bone marrow ECM is in influencing proliferation, differentiation, and cell
adhesion of developing myelopoietic, erythropoietic and more mature B-lineage cells
(148-151).
V.

Bone Marrow Homing
Lethal doses of chemotherapy or irradiation result in the ablation of

hematopoiesis and ultimately death. In 1951, Lorenz, et al. demonstrated that lethally
irradiated mice could be rescued if these mice received a bone marrow transfusion from
a genetically identical littermate (121). This was the first demonstration of successful
bone marrow transplantation in animals and established proof for the concept of cellular
hematopoietic recovery, as opposed to protective humoral factors (121;152). The first
allogeneic bone marrow transplantation occurred in 1954 (153).

Lorenz, et al.

demonstrated that lethally irradiated mice could be rescued with intravenously injected
rat bone marrow (153).

These and other animal model studies eventually lead to

clinical trials in humans by the late 1950’s.
From 1958 to 1962, 154 patients had undergone bone marrow transplantation
(154). The majority of these bone marrow transplants failed due to various causes
including inadequate pretreatment of the patient, infection, or graft-versus-host disease
(GVHD).

Human bone marrow transplant studies were greatly reduced for the

remainder of the 1960’s.

Of particular interest from these initial trials, was the

observation that of the seven patients who underwent syngenic bone marrow
transplantation, five patients (71%) had displayed complete clinical recoveries. Less
than 25% of other cases at this time survived and in those who survived transplantation
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disease progression continued (154). While the process of homing to, and engraftment
within, the bone marrow was poorly understood, histocompatibility issues, GVHD, and
other transplantation complications became major focal points at that time and research
in these areas remains ongoing (154-156).
In 1993, Tashiro, et al. isolated the chemotactic factor SDF-1 and a heightened
interest in characterizing the process of stem cell homing to the bone marrow began
shortly after (140;157;158). Between 1996 and 2002, characterization of SDF-1 (CXCL12) and CXCR-4 and their relationship to homeostasis of bone marrow hematopoiesis,
has been intensely studied.
Hematopoietic cell migration to and retention within hematopoietic bone marrow
requires establishment of local SDF-1 concentration gradients (7;140;159;160). SDF1α, a member of the C-X-C chemokine family, is an 89 amino acid soluble protein that
promotes CXCR4+ cell chemotaxis. SDF-1β is a minor isoform of SDF-1 generated by
alternative splicing and contains 4 additional amino acids (161).

SDF-1 is highly

conserved in mice and humans, with only one amino acid difference between species.
The only known endogenous ligand for SDF-1 is CXCR-4, which is predominantly
expressed on CD34+ stem cells, pro- and pre-B cells, T-lymphocytes, monocytes, and
some leukemic cells (162).

Phenotypic manifestations of SDF-1-/- and CXCR-4-/-

knockout mice are almost identical.
embryogenesis (~E18.5).

Both homozygous mutant mice die during

They fail to establish bone marrow lymphopoiesis and

myelopoiesis, display normal thymic T-cell development, and have reduced fetal liver
myeloid cell development (139-141).
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The requirement for SDF-1 in bone marrow homing is well documented.
However, the specific roles of various adhesion molecules in bone marrow homing are
not as clear. There are only two known adhesion molecules uniquely found in the bone
marrow. These include lectins found on stem cells (163) and hemonectin found in the
bone marrow microenvironment (150).

While unique addressins have not been

identified that confer bone marrow homing specificity (as seen in homing to mucosal
tissues (MadCAM-1 and α4β7) (164)), other unique qualities of the bone marrow,
including that of the bone marrow microvasculature, contribute to the specificity of
homing. Data suggest that 18-20% of engrafted stem cells home to bone marrow (165).
Bone marrow homing is specific as suggested from observations of 20% bone marrow
homing versus bone marrow receiving only 2-4% of cardiac output (166)). Finally, given
the correct microenvironment, engraftment (initiation of hematopoiesis) follows (167).
No single adhesion molecule has been demonstrated to be solely required for
bone marrow homing to date. Instead, hematopoietic stem and progenitor cell homing
specificities are the result of the coordinated effort of several adhesion molecules and
their

distinctive

anatomical

constitutive

expression

within

the

bone

marrow

microvasculature. Unlike other vascular endothelial cells, bone marrow endothelial cells
(BMEC) constitutively express E-selectin and VCAM-1, and both have been shown to
contribute to bone marrow homing specificity (168-171).
In the first stage of bone marrow homing hematopoietic progenitor and stem cells
interact with bone marrow endothelial cells in specialized capillaries termed sinusoids.
At the bone marrow sinusoids, cellular exchange is active between the vascular lumen
and extravascular spaces. Hematopoietic progenitor and stem cell interactions with E-
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selectin (CD62E) and P-selectin (CD62P) result in rolling of hematopoietic cells along
the vasculature (168-170). As the hematopoietic cells roll along the lumen of the bone
marrow sinusoid, BMEC expression and presentation of SDF-1 induces progenitor and
stem cells integrin activation (or clustering) and strong adherence (162;172-178). This
is followed by arrest, mediated by BMEC VCAM-1 and hematopoietic progenitor and
stem cell α4β1 (VLA-4) interactions (168;179).

In an E-selectin-mediated process,

transendothelial cell migration from the lumen of the bone marrow sinusoid to the
extravasculature space (bone marrow microenvironment) completes the homing phase
(168;180).
Engraftment is defined by lodgment and expansion of hematopoietic cells within
sustaining microenvironments. Once in the correct extravascular space, hematopoietic
stem cell engraftment leads to hematopoietic recovery. Adhesion interactions within
bone marrow microenvironments are unique and stem cell mobilization must overcome
these adhesive interactions to allow reverse migration (egress) from the bone marrow
microenvironment to the sinusoidal luminal spaces.
VI.

Bone Marrow Mobilization
Hematopoietic cell retention within the bone marrow microenvironment relies on

a complex interplay of adhesion molecule interactions.

Molecular and signaling

alterations that result in the egress of hematopoietic progenitor and stem cells from the
bone marrow to the periphery are not completely elucidated. Current mobilizing agents
are characterized by their ability to mobilize stem cells to the periphery with minimal
side effects, as opposed to an understanding of their underlying mechanisms (181). GCSF mobilization is the most widely utilized stem cell mobilizing strategy (22;181;182).
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Other mobilizing agents have been evaluated including SCF, IL-11, IL-8, and Flt-3
ligand, but they have not been shown to better mobilize hematopoietic progenitor and
stem cells than G-CSF (183).
G-CSF induced hematopoietic stem cell mobilization generates a 40- to 80-fold
increase in peripheral hematopoietic progenitor and stem cells following 4 to 5 days of
treatment (184;185). Optimal peripherilization is preceded by bone marrow neutrophil
granulopoiesis (186).

Until recently, the mechanism of G-CSF induced stem cell

mobilization remained unknown. In late 2001, Lévesque, et al. proposed a model that
detailed potential mechanisms underlying G-CSF-induced hematopoietic progenitor and
stem cell mobilization.

During G-CSF mobilization, bone marrow neutrophil

accumulation and increased release of two serine proteases, neutrophil elastase and
cathepsin G, was shown to result in stromal cell VCAM-1 cleavage and stem cell
mobilization. While stromal cell VCAM-1 was reduced, bone marrow vascular VCAM-1
and VCAM-1 levels in the spleen remain unchanged, accounting for the observation of
hematopoietic cell splenic homing and increased spleen mass (22). This work further
supports a central role for bone marrow stromal cell VCAM-1 interactions with
hematopoietic progenitor and stem cell α4β1 (VLA-4) in hematopoietic cell bone marrow
extravascular space retention (22;82;84;97;169;187-190).
Given these data, it is tempting to attribute hematopoietic progenitor and stem
cells retention within the bone marrow solely to VCAM-1 interactions with α4β1 (VLA-4).
However, the complex interplay of various other adhesion molecules, their activity, and
signaling also impact hematopoietic cell bone marrow retention and mobilization.
Several mobilizing strategies result in consistent reductions of hematopoietic stem cell
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LFA-1 and LFA-3 in addition to VLA-4. Negligible change has been observed in CD-31,
CD-44, and CD-62L (L-selectin) expression (191-193). It is currently unknown how
alterations in hematopoietic progenitor and stem cell adhesion molecule profiles are
regulated following mobilizing strategies, but the central role of VCAM-1:α4β1 (VLA-4)
interactions in bone marrow hematopoietic cell retention are well established.
VII.

Bone Marrow Microenvironment Damage
Irradiation and/or chemotherapy are common treatment strategies associated

with many forms of cancer. Irradiation in conjunction with high-dose chemotherapy is
commonly utilized prior to bone marrow transplantation (BMT) to optimize residual
tumor cell death. Many studies have shown that delays in immune system recovery are
associated with different treatment regimes in preparation for BMT. Of interest is that
functional recovery of specific blood cell lineages (e.g. myeloid, erythroid, and lymphoid)
occur at distinct times following BMT, and a common observation involves prolonged
deficits in the B-cell compartment (19;23;194-198). Studies that evaluated enhanced
restoration of B-lymphopoiesis by addition of exogenous lymphoid specific cytokines
such as IL-7 have shown promise, but suboptimal microenvironmental support and
tumor generation from excess exogenous IL-7 remain valid concerns (199-201). There
have also been encouraging reports of lymphoid cell restoration when healthy stromal
cells are co-infused with hematopoietic cells during bone marrow transplantation
(195;196;202).

These

observations

suggest

that

specific

bone

marrow

microenvironments (i.e. those that favor B-cell development) are altered or sustain
prolonged damage following high dose chemotherapy and BMT.
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Bone marrow stromal cells are primarily non-cycling and relatively resistant to
apoptosis induced by chemotherapy or irradiation (119;203;204). However, stromal cell
resistance to cytotoxic agents appears to vary depending on several factors including
the specific cytotoxic agent, dose, and experimental method utilized to test for functional
damage (205-209). Several groups have demonstrated that both chemotherapy and
irradiation can damage stromal cells, leading to a reduced capacity to both support
efficient hematopoiesis and to self-renew (205;207). Stromal cell damage was identified
as altered production of cytokines (reduced G-CSF (210), increased TNF-α (211) and a
reduced ability of self-renewal, quantitated by a decrease in the frequency of fibroblastic
colonies formed in vitro (CFU-F) from treated subjects (207;208;212).
Importantly, previous studies have not addressed the altered function of stromal
cells related to individual drugs. One group reported that patients irradiated and treated
with multi-drug chemotherapy had a reduced ability to establish CFU-F’s for up to
twelve years following treatment cessation (207).

These data suggest an impaired

capacity of stromal cell self-renewal, but they do not address alterations in the capacity
of stromal cells to contribute to homing of progenitor cells or to support hematopoiesis.
A group of studies have specifically focused on disruption of stromal cell
adhesion molecule expression as one component of treatment induced damage.
Gibson, et al. demonstrated that stromal cell cultures treated in vitro with etoposide had
reduced ability to support lymphoid cell proliferation and diminished VCAM-1 protein
expression (213).

Although data from several groups suggest the potential for

chemotherapy-induced damage of the microenvironment, the molecular mechanisms
that underlie reported damage remain to be determined. In addition, no reports provide
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description of how aggressive chemotherapy exposure may alter the signals that
regulate homing of healthy progenitor cells, as in the transplantation setting.
A functional bone marrow microenvironment is essential not only during normal
hematopoiesis, but also to facilitate recovery of hematopoietic populations following
chemotherapy or irradiation (131).

Recovery relies on both homing of healthy

progenitors to the marrow and appropriate development once seeded in the correct
microenvironmental niche.

Long-term damage to the immune system following

aggressive chemotherapy suggests that, in addition to stem cell damage, there is
potential

disruption

of

(23;26;27;131;194;195;211;214;215).

the

bone

marrow

microenvironment

This damage may result in both disruption of

stromal cell directed homing of progenitor cells to the bone marrow and diminished
support of those progenitor cells that do traffic to the marrow. While microenvironment
damage is likely diverse, alterations in VCAM-1 and SDF-1 expression following
chemotherapy are essential areas to investigate. VCAM-1 and SDF-1 define unique
and specific stromal cell derived elements of the bone marrow microenvironment to
which strategies to maintain or restore function following treatment could be applied.
VIII.

Corrective medical intervention strategies
Myelosuppressive doses of chemotherapy and/or irradiation in preparation for

bone marrow transplantation (BMT) ablate bone marrow hematopoiesis and leave
patients in a fragile immunologic state until engrafted bone marrow reestablishes
hematopoiesis. Following high dose chemotherapy, immediate corrective measures to
counter anemia, thrombocytopenia and neutropenia are imperative for enhancing
survival of patients.

While blood transfusions are sufficient to offset anemia and
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thrombocytopenia, absolute neutrophil count (ANC) restoration requires bone marrow
hematopoietic restoration. Attempts to enhance hematopoietic (myelopoietic) recovery
in BMT patients include use of exogenous growth factors such as G-CSF, GM-CSF,
SCF, IL-3, and IL-6. These growth factors enhance bone marrow myelopoiesis leading
to improved patient ANC recovery times (216-227).
Immediate concerns following BMT are in restoration myelopoietic functions as
delays in humoral (B-cell) and cell-mediated (T-cell) immunity can be offset using
antifungal and antibacterial agents.

However, long-term delays in humoral or cell-

mediated immunity increase the risk of pathogen resistance and infection.

Some

studies have demonstrated that recombinant IL-7 treatment following BMT and other
chemotherapeutic treatment strategies leads to enhanced B and T-cell recoveries (228230).

Variability in exogenous growth factor restoration of hematopoiesis may be

explained by differential damage to the bone marrow microenvironment caused by
different cytotoxic agents. In addition to exploring the ability of exogenous cytokines to
enhance B-lymphopoiesis, several recent studies have suggested that co-infusion of
bone marrow stromal cells following high-dose chemotherapy enhances lymphopoiesis
and B-cell recovery (196;202).

These strategies may be better suited to B-cell

restoration following BMT in conjunction with cytotoxic treatment strategies that severely
damage the bone marrow microenvironment.
IX.

Summary and Goals
Numerous adhesion molecules, cytokines, chemokines, extracellular matrix

proteins, and other soluble factors influence and regulate steady state hematopoiesis.
Two proteins appear to be critical for successful homing of hematopoietic to the bone
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marrow, the stromal cell adhesion molecule VCAM-1 and the stromal cell-derived
chemokine SDF-1. In addition to their roles in homing, VCAM-1 and SDF-1 have been
shown to support B cell development and proliferation respectively. Following ablative
therapies in preparation for bone marrow transplantation, reductions in stromal cell
VCAM-1 and/or SDF-1 potentially have serious clinical consequences reflected as a
patient’s diminished ability to support bone marrow homing and restoration of
hematopoiesis.

Understanding the molecular mechanisms that underlie altered

expression of VCAM-1 and SDF-1 could lead to treatment strategies that would restore
efficient bone marrow homing and enhance the kinetics of hematopoietic recovery
following bone marrow transplantation.
The focus of the current study was to begin to define bone marrow
microenvironment damage following high dose chemotherapy that may contribute to
prolonged immune system deficits.

Characterization of bone marrow stromal cell

damage following dose escalated chemotherapy in vitro may lend insight to the
observed deficits in B-cell restoration following bone marrow transplantation. Using in
vitro models, the impact of aggressive chemotherapy on stromal cell production of
VCAM-1 and SDF-1 has been characterized. Dysregulation of these two critical stromal
cell derived proteins following exposure to chemotherapy correlates with observed
delays in immune system reconstitution documented clinically.
In this study, etoposide (VP-16) was chosen as a model chemotherapeutic drug
due to common clinical use at escalated doses (26;231-234). In the first aim, alterations
in stromal cell SDF-1 production following drug exposure were characterized.
Experiments in the second aim evaluated molecular mechanisms that underlie down
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regulation of stromal cell VCAM-1 following chemotherapy exposure.

Finally,

experiments completed in the third aim established and characterized a model that may
be beneficial in determining the impact of altered VCAM-1 expression on the ability of
stromal cells to support hematopoiesis in vitro.
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ABSTRACT

An essential component of successful bone marrow transplantation is the
efficient chemotaxis of transplanted hematopoietic progenitor cells to the bone marrow.
Stromal cell derived factor-1 (SDF-1) is a primary chemokine responsible for
chemotaxis of hematopoietic cells to the marrow microenvironment.

To determine

whether aggressive chemotherapy reduces SDF-1 expression or the ability of stromal
cells to support progenitor cell chemotaxis, we evaluated the effect of etoposide or
doxorubicin on stromal cell SDF-1 production. SDF-1 protein was reduced following
exposure of stromal cells to either topoisomerase II inhibitor. In addition, chemotherapy
treated stromal cells failed to support leukemic cell or normal pro-B cell migration.
These data suggest that specific chemotherapeutic agents may contribute to delayed
hematopoietic recovery, in part, through reduction of stromal cell SDF-1 expression in
the bone marrow microenvironment.
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INTRODUCTION
Homing of hematopoietic progenitor cells to the bone marrow during normal
development, or following transplantation, is a multi-step process {1;2}. It is essential
that progenitor cells marginate, transition from rolling to strong interaction with the
luminal surface of the bone marrow endothelium, and undergo diapedesis. Following
transit through the endothelium, hematopoietic cells migrate to stromal cell niches in the
microenvironment that are capable of supporting their survival, proliferation, and
differentiation. A cascade of interacting integrins, adhesion molecules, and extracellular
matrix proteins regulate this complex process.

The chemokine stromal cell derived

factor-1 (SDF-1) has been shown to be essential for the directed movement of
hematopoietic progenitor cells from the periphery to the bone marrow and for their
subsequent migration through the extracellular matrix to the stromal cell surface {3-6}.
SDF-1 was originally identified in the stromal cell line PA6 as a soluble factor that
synergized with IL-7 induced proliferation of pre-B DW34 cells {7}. The deduced
nucleotide sequence for SDF-1 was homologous with a factor identified earlier as a
secreted protein by signal sequence trapping {8}.

The chemoattractant found in

supernatants of murine stromal cell lines MS-5, PA-6, and ST-2, was identified as SDF1 based on amino acid identity {5;7;9}. SDF-1 is now known to play a definitive role in
homing of hematopoietic progenitor cells to the bone marrow microenvironment.
Knock-out mice that lack SDF-1 expression or its G-protein coupled receptor, CXCR4
{10-13} suffer both cardiac and hematopoietic defects {14-16}. SDF-1 knockout mice
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have markedly reduced B lymphopoiesis and complete absence of myelopoiesis in the
bone marrow {15}. In CXCR4 defective mice, myeloid cell development in the fetal liver
was demonstrated to be normal, but cellularity of the bone marrow was markedly
reduced {14}. In addition, studies have shown that anti-CXCR4 antibody treated human
CD-34+ stem cells failed to engraft in NOD/SCID mice recipients {17}. Reports based
on in vivo models have been substantiated by in vitro studies that demonstrated a role
for SDF-1 directed homing of progenitors to the marrow and direct effects on survival
and proliferation of hematopoietic cells {18}.

Importantly, hematologic recovery of

patients following transplantation has recently been shown to be most efficient in
patients who received CD34+ cells that responded efficiently to SDF-1 in vitro {19}.
We previously reported that VP-16 exposure disrupted stromal cell capacity to
support lymphoid and myeloid cell expansion, and that this diminished capacity was
correlated with reduced expression of the stromal cell adhesion molecule VCAM-1 {20}.
In the present study, we investigated the effect of VP-16 and doxorubicin on stromal
cells to determine whether their ability to support migration of a CXCR4+ leukemic cell
line, JM-1, was also impaired by treatment. Both drugs impose DNA strand breaks
using a Topoisomerase II dependent mechanism.

Our data demonstrate that

chemotherapy treated human bone marrow stromal cells secrete reduced amounts of
SDF-1 protein and have an impaired capacity to support JM-1 cell migration compared
to untreated cells. Reduced SDF-1 secretion was sustained for five days following
removal of drug.

Taken together, these observations support the hypothesis that

delayed hematopoietic recovery following dose intensive chemotherapy may be due, in
part, to diminished stromal cell SDF-1 production.
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MATERIALS AND METHODS

Cell Lines
Stromal cell cultures were initiated from human bone marrow from consenting
donors, with approval by the West Virginia University Institutional Review Board, as
previously described {20}. All stromal cell primary cultures were initiated from donors
with no previous chemotherapy exposure. The JM-1 factor independent lymphoblastic
leukemic cell line, (#CRL-1873; HLA DR+, CD10+, CD19+, surface Ig-, VLA-4+, VLA-5-,
CXCR-4+) was purchased from the American Type Culture Collection (ATCC). JM-1
cells were maintained in Iscoves medium supplemented with 10% ATCC Fetal Bovine
Serum, 2mM L-Glutamine (GibcoBRL; Rockville, MD), 100U/ml Penicillin (Sigma; St.
Louis, MO), 100µg/ml Streptomycin (Sigma), 5x10-5M β-mercaptoethanol (Sigma).
Chemotherapeutic agents
VP-16 (Sigma) was mixed at a stock concentration of 20mg/ml (100mg VP-16,
650mg polyethylene glycol 300, 80mg Tween 80 (ultra pure), 30.5% ethanol, 2mg citric
acid, 30mg benzyl alcohol) and diluted to 0.1-100 µM in culture medium immediately
prior to use. We have previously determined that matched vehicle doses do not impact
on stromal cell SDF-1 secretion (data not shown).

100µM VP-16 was chosen to

approximate serum levels reported for patients on high dose therapy {23}. Doxorubicin
(Gensia Laboratories; Irvine, CA) was diluted to 0.1µM to 10µM in culture medium to
approximate the range of serum concentrations found in patients receiving this drug
{24-26}. Based on its association with cardiac toxicity when used at escalated doses
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{30-31}, a maximum dose of 1.0 µM doxorubicin is used in most experiments as a
clinically relevant level. Both chemotherapeutic drugs were stored at 4oC prior to use.
SDF-1 ELISA
Confluent stromal cells, in 96-well tissue culture dishes (Becton Dickinson;
Franklin Lakes, NJ), were treated with 0.10µM - 100µM VP-16 or 0.10µM - 10µM
doxorubicin for up to 24 hours. Following treatment, cells were rinsed three times with
fresh medium, and 110µl of serum-free Iscoves medium placed in each well. Plates
were returned to 37o for 24 hours, and 100µl of the 24-hour stromal cell conditioned
supernatant was collected from each well to evaluate SDF-1 protein by ELISA, following
the recommendations of the manufacturer (R&D Systems, Inc.; Minneapolis, MN). The
limit of SDF-1 protein detection as stated by the manufacturer ranged from 1-47pg/ml,
which fell well below our lowest stromal cell SDF-1 protein concentration. All treatment
groups were evaluated in triplicate.
RNA isolation
Total RNA was isolated from confluent stromal cells treated with 100µM VP-16 or
1.0µM doxorubicin using the S.N.A.P. Total RNA Isolation kit following the
recommendation of the manufacturer (Invitrogen; Carlsbad, CA). Pelleted stromal cells
were lysed by centrifugation through QIAshredder Spin Columns (QIAGEN Inc.; Santa
Clarita, CA). RNA was DNase treated and quantitated at 260nm (GENESYS-10UV;
Spectronic Unicam; Rochester, NY).
Reverse Transcriptase – Polymerase Chain Reaction (RT-PCR)
To evaluate SDF-1 and β-actin RNA levels, “One-Step” RT-PCR (Qiagen Inc.;
Valencia, CA) was completed using RNA isolated from untreated, VP-16 treated, and
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doxorubicin treated stromal cells.

Reverse transcription and amplification cycles

included 50o-30min, 95o-15min, and 30 cycles of 94o-30sec, 55o-1min15sec, 72o2min15sec (Perkin-Elmer GeneAmp PCR System 9600). Samples included 0.1µg of
total RNA isolated from treated and untreated stromal cells as indicated above. Actin
primers

were:

5’-TGACGGGGTCACCCACACTGTGCCCATCTA-3’

CTAGAAGCATTTGCGGTGGACGATGGAGGG-3’

(Stratagene;

0.1µg/reaction to generate an amplicon of 661 base pairs.

La

and

Jolla,

5’-

CA) at

SDF-1 primers: 5’-

GCCATGAACGCCAAGCTCGTGGT-3’ and 5’-CCTCGAGTGGGTCTAGCGGAAAG-3’,
(0.4µg/reaction) generated an amplicon of 317 base pairs {27}. As a negative control,
samples that lacked RNA were included in all experiments. SDF-1:actin ratios were
quantitated by EagleSight Version 3.21 (Stratagene; La Jolla, CA) densitometric
analysis.
Chemotaxis assay
Migration of the CXCR-4+ cell line JM-1 toward treated and control stromal cells
across 5µm pores was determined using 6.5mm diameter tissue culture treated
transwells (Corning, Inc.; Corning, NY). Confluent stromal cell layers, grown in 24-well
tissue culture plates (Becton Dickinson; Franklin Lakes, NJ), were treated with 1.0µM or
100µM VP-16, 0.1µM or 1.0µM doxorubicin, or left untreated for 24 hours. As noted
previously, the highest dose of each drug represents that typically used at the maximal
level.

Stromal cells were then rinsed three times with fresh medium and 350µl of

Iscoves medium was placed in each well. Following 24 hours, 5µm transwells were
placed into each well and 80,000-120,000 CXCR-4+ JM-1 cells in a volume of 150µl
Iscoves medium were placed in the top chamber. To evaluate the ability of SDF-1 to
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restore migration toward chemotherapy pretreated stromal cells, 5ng/ml SDF-1 was
added to matched wells in each treatment group. Transwells were incubated at 37o C
for 4.5 hours. Cells migrating to the lower chamber were enumerated and percent JM-1
chemotaxis was determined as percent of control chemotaxis.

Negative control

samples included medium only in the lower chamber to evaluate spontaneous migration
(less than 10% of positive controls at all times tested – data not shown), and positive
control wells included 5ng/ml recombinant human SDF-1 (rSDF-1) in the lower
chamber.
Recovery of stromal cell SDF-1 expression
Stromal cells were exposed to 100µM VP-16 for up to 72 hours or cultured in
medium alone. Following treatment, cells were rinsed, resuspended in fresh medium,
and cultures maintained for up to 5 days. Supernatants were removed and replaced
one day before SDF-1 ELISA analysis with serum-free Iscoves complete medium as
previously described.
Recovery of stromal cell ability to support JM-1 cell migration
Stromal cell layers were treated for 24, 48, or 72 hours with 100µM VP-16. Cells
were either evaluated immediately following treatment or following 3 days of recovery.
24 hours prior to initiation of assays, supernatants were replaced by 350µl fresh
medium on all wells. Migration was evaluated as percent of control (untreated stromal
cells), as previously described.
Statistical analysis
Statistical analysis was performed using One Way Analysis of Variance and
Tukey Test to detect differences among means (SigmaStat Version 2.0 software, SPSS
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Inc.; Chicago, IL). All statistical comparisons represent treated samples as compared to
control levels.

All controls were matched to the longest treatment groups in each

experiment.
RESULTS
VP-16 or doxorubicin exposure reduces bone marrow stromal cell SDF-1 protein
expression
To determine whether topoisomerase II inhibitors VP-16 or doxorubicin alter
stromal cell production of SDF-1, we evaluated several independent primary human
stromal cell lines for SDF-1 protein production by ELISA following exposure to each
drug. SDF-1 protein was reduced in stromal cell supernatants in a dose-dependent
manner following exposure to either drug (Figure 1A). Secreted SDF-1 protein was
reduced to approximately 70% of untreated control levels when stromal cells were
treated with either 0.1µM doxorubicin or 1.0µM VP-16 for 24 hours. When cells were
exposed to 1.0µM doxorubicin or 100µM VP-16 for 24 hours, greater reductions to 4050% of untreated control levels were observed (Figure 1A). SDF-1 protein reductions to
39% and 30% of baseline levels were observed when cells were exposed to the highest
doses tested, 100µM VP-16 and 10µM doxorubicin respectively (P<0.05).
SDF-1 protein production by fifteen independent human stromal cell lines was
evaluated in triplicate in two independent experiments. A mean stromal cell SDF-1
protein reduction of 63±2.1% (S.E.) (P<0.05 ; each cell line), relative to untreated
stromal cells, was observed following 24 hour exposure to 100µM VP-16 (Figure 1B).
SDF-1 protein reduction was not due to decreased stromal cell viability in these
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experiments (data not shown). Consistent with our previously published report {20},
viability of treated stromal cells remained greater than 95% (data not shown).

Bone

marrow

stromal

cell

SDF-1

message

level

is

reduced

following

chemotherapy treatment
In contrast to SDF-1 protein, SDF-1 mRNA levels were only modestly decreased
following stromal cell drug exposure. Bone marrow stromal cells were exposed to 1 µM
doxorubicin or 100µM VP-16 for up to 24 hours, and RT-PCR amplified SDF-1 RNA
levels were compared to the housekeeping gene, actin, as previously described. Less
than 30% reductions in SDF-1 transcript levels were observed following treatment with
100µM VP-16 (Figure 2A) or 1 µM doxorubicin (Figure 2B) for up to 24 hours. SDF-1
message levels remained at 70-80% of control levels following up to 48-hour
doxorubicin or VP-16 exposures (data not shown).

Chemotherapy diminishes stromal cell-induced migration of JM-1 cells
To determine whether reduced stromal cell SDF-1 protein following drug
exposure correlated with a reduced functional capacity of chemotherapy treated stromal
cells, we evaluated JM-1 cell migration in vitro utilizing transwell assays. Consistent
with reduced SDF-1 protein, chemotherapy treated stromal had reduced capacity to
support JM-1 chemotaxis. When compared to JM-1 cell migration toward untreated
stromal cell layers, JM-1 migration toward stromal cells was reduced to 44.7% (P<0.05),
following 1µM VP-16 treatment of stromal cells and further reduced to 40.2% (P<0.05)
in response to 100µM VP-16 treated stromal cells (Figure 3A). JM-1 chemotaxis toward
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0.1µM doxorubicin pre-treated stromal cells was 55.2% (P<0.05) of the chemotaxis
observed for JM-1 cells toward untreated stromal cells. A further reduction in JM-1 cell
migration to 45.8% of untreated control levels (P<0.05) was observed when stromal
cells were treated with 1.0µM doxorubicin (Figure 3B). JM-1 cell movement toward
medium alone was consistently less than 10% of that observed towards 5ng/ml rSDF-1
or untreated stromal cell layers.

Recombinant SDF-1 restores JM-1 movement toward chemotherapy damaged
stromal cells
To determine whether chemotherapy treated stromal cells produced factors that
inhibit JM-1 cell chemotaxis, migration toward chemotherapy treated stromal cells,
supplemented with recombinant SDF-1 was evaluated. Addition of exogenous rSDF-1
to the conditioned medium from treated stromal cells restored JM-1 cell chemotaxis to
that of untreated stromal cell layers (Figures 3A and 3B).

SDF-1 protein expression does not recover for up to 5 days following removal of
drug
Some high dose treatment strategies that include VP-16 include a 60-hour
intravenous transfusion period {23}. To evaluate the effect of prolonged exposure on
stromal cell SDF-1 protein levels, stromal cells were treated with VP-16 for up to 72
hours, rinsed, and allowed to recover for up to 5 days. All wells had fresh serum-free
medium added 24 hours prior to SDF-1 protein evaluation by ELISA. VP-16 exposure
for 72 hours resulted in decreased SDF-1 protein levels, with the decrease sustained
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during a 5 day recovery period (Figure 4).

SDF-1 protein was reduced to

approximately 40% of baseline (P<0.05) when stromal cells were treated with 100µM
VP-16 for 72 hours. Viability of confluent stromal cells treated with VP-16 for 72 hours
consistently remained greater than 95% (data not shown). Sustained SDF-1 reductions,
20-30% of untreated control stromal cells (P<0.05), were maintained when cells were
allowed to recover for up to 5 days following cessation of treatment (Figure 4).

Sustained deficits in stromal cell SDF-1 protein expression by chemotherapy
treated stromal cells correlate with impaired ability to support JM-1 cell migration
To address the functional consequence of reduced stromal cell SDF-1 following
VP-16 treatment and recovery, migration of JM-1 cells toward treated and control
adherent stromal cell layers was evaluated as described. The ability of VP-16 treated
stromal cells to support JM-1 chemotaxis was diminished during exposure to VP-16 and
did not recover for up to 3 days following removal of drug (Figure 5). JM-1 chemotaxis
toward stromal cells was reduced to approximately 40% (P<0.05) following 100µM VP16 treatment of stromal cells for up to 72 hours. Stromal cell deficits were sustained for
up to 3 days following removal of the drug.

DISCUSSION
The role of SDF-1 as a major chemoattractant responsible for hematopoietic cell
homing to the bone marrow has only recently been fully appreciated {3-6;19}.
Hematopoietic cell chemotaxis to, and retention within, the bone marrow relies in part
on local and peripheral SDF-1 concentration gradients {28}.

62

SDF-1’s only known

endogenous ligand is CXCR4, which is predominantly expressed on CD34+ stem cells,
pro- and pre-B cells, T-lymphocytes, monocytes, and many leukemic cells {1;3-6;29}. In
the current study, we tested the hypothesis that topoisomerase II inhibitors disrupt bone
marrow stromal cell by reducing stromal cell SDF-1 protein production, using VP-16 and
doxorubicin as model drugs. While a range of doses was tested for each drug, to
evaluate their potential to reduce stromal cell SDF-1 expression, the maximal dose used
most commonly in clinical settings was chosen as the focus of the migration assays.
Our data demonstrate that both topoisomerase II inhibitors tested reduce stromal cell
SDF-1 protein expression in all independent primary human stromal cell lines evaluated.
In addition, the ability of stromal cells to support chemotaxis of JM-1 cells was markedly
reduced by stromal cell exposure to either chemotherapeutic agent.

These data

suggest a functional alteration of bone marrow stromal cells by two agents that are
commonly included in chemotherapy treatment regimens.
VP-16 may be the most clinically relevant drug in our in vitro transplantation
model because it is tolerated by patients at escalated doses, while doxorubicin use at
high levels is limited by cardiac toxicities {30;31}.

Interestingly however, both

topoisomerase II inhibitors decreased SDF-1 production by stromal cells, while cytosine
arabinoside (Ara-C) or 4-hydroxycyclophosphamide (4-HC; the primary active
metabolite of cyclophosphamide) treatment had no effect (data not shown).

These

observations suggest that reduction of stromal cell SDF-1 production may be unique to
specific drugs, or classes of drugs, such as topoisomerase II inhibitors. In a recent
publication, increases in bone marrow SDF-1 expression were observed following
irradiation or treatment with cyclophosphamide or 5-FU in mice {32}. In the current
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study, no increase in stromal cell SDF-1 protein level resulted from 4-HC exposure.
Discrepancy between our results and the previous report may stem from our use of the
active metabolite, 4-HC, in contrast to the parental compound, cyclophosphamide.
Stromal cell exposure to the topoisomerase II inhibitors VP-16 or doxorubicin
reduced SDF-1 protein production (Figure 1) without impacting on cell viability.

In

contrast to SDF-1, preliminary experiments indicated increased expression of secreted
SCF and stable expression of MIP-1α protein by VP-16 treated stromal cell layers
compared to untreated controls (data not shown). These observations suggest that VP16 treatment does not result in a general reduction of protein synthesis or stability, but
rather has specific effects on unique stromal cell derived factors.

Reduced SDF-1

protein production following treatment correlated with impaired ability of bone marrow
stromal cells to support directional JM-1 cell movement (Figure 3A). Primary human
stromal cell production of SDF-1 protein ranged from 1300-3600pg/ml. When exposed
to VP-16 or doxorubicin, primary human stromal cell lines consistently demonstrated
reduced SDF-1 production and diminished ability to promote JM-1 cell migration. In
addition to JM-1 cells, we evaluated chemotaxis of the CXCR4+, SDF-1 responsive cell
lines SUP-B15 (human pre-B ALL) and C1.92 (nontransformed murine pro-B cell clone
{22}), as indicators of stromal cell mediated chemotaxis. A consistent trend of reduced
migration of these additional lines toward chemotherapy treated stromal cells was
observed (data not shown).
Decreases in stromal cell SDF-1 protein following exposure to VP-16 or
doxorubicin were not reflected at the SDF-1 RNA level (Figure 2). These data suggest
alteration of SDF-1 may be due to post-transcriptional mechanisms. Protein transport or
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general translational alterations are unlikely responsible for this observation based, in
part, on the observed increases in secreted SCF and maintenance of MIP-1α following
VP-16 exposure noted earlier.
Previous studies have shown that stromal cells established from chemotherapy
treated patients inhibit generation of CFU-GM from CD34+ progenitor cells in vitro {33}.
To determine whether VP-16 or doxorubicin induced stromal cell factors that inhibit JM1 cell chemotaxis, exogenous rSDF-1 was added to the supernatants of chemotherapy
pre-treated stromal cells and evaluated restoration of migration. Addition of rSDF-1 to
chemotherapy damaged stroma resulted in restoration of hematopoietic cell migration
suggesting that SDF-1 protein reduction, in contrast to chemotherapy induced inhibitors,
is a key factor in decreased stromal cell support of JM-1 cell chemotaxis following
treatment (Figure 3B).
In some experiments, JM-1 cell migration toward stromal cell monolayers
exceeded that of chemotaxis towards rSDF-1 alone. This observation is potentially
explained by the combination of endogenous stromal cell SDF-1 and stem cell factor
(SCF).

SCF has been previously demonstrated to enhance hematopoietic cell

chemotaxis in the presence of SDF-1 {3}.

However, a previous report has

demonstrated that even high levels of SCF cannot support chemotaxis of CXCR4
positive cells when SDF-1 availability is limited {3}.
Sustained deficits in hematopoietic recovery have been noted following high
dose chemotherapy and bone marrow transplantation in many studies {34-36}.
Consistent with delays in hematopoietic recovery following chemotherapy treatment, we
did not observe restoration of SDF-1 protein levels from chemotherapy treated stromal
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cells for up to 5 days of recovery (Figure 4).

This correlated with a functional

impairment of chemotherapy treated stromal cells as well (Figure 5).

Additional

experiments will be necessary to evaluate extended periods of recovery, however, the
current experiments are limited by the finite amount of time a confluent layer of stromal
cells can be maintained in vitro.
The appropriate expression of stromal cell chemokines, adhesion molecules, and
cytokines define the ability of the microenvironment to support hematopoiesis.
Previously, we have reported that human stromal cells exposed to VP-16 have reduced
VCAM-1 protein {20}. In addition, we have found that doxorubicin also disrupts stromal
cell VCAM-1 protein (unpublished data). In the current report, we demonstrate that
these same chemotherapeutic agents also reduce stromal cell SDF-1 production.
Taken together, these observations suggest that specific chemotherapeutic agents may
blunt hematopoietic reconstitution by disrupting factors that underlie progenitor cell
chemotaxis to, or retention within, appropriate stromal cell niches of the marrow
microenvironment.
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FIGURE LEGENDS
Figure 1.

VP-16 and doxorubicin reduce bone marrow stromal cell SDF-1 protein

expression. To quantitate stromal cell SDF-1 protein expression following chemotherapy
treatment, confluent stromal cell layers were treated with (A) 0.10µM to 100µM VP-16 or
0.10µM to 10µM doxorubicin for up to 24 hours or (B) 100µM VP-16 for 24 hours.
Following treatment, cells were rinsed, and 110µl of serum-free medium placed in each
well. Following 24 hours incubation, 100µl of conditioned supernatant was collected
from each well for evaluation by ELISA.

All treatment groups were evaluated in

triplicate. Means ± SE are shown at each point. Data shown represents (A) a minimum
of 3 independent experiments (cell lines: Ped299, P156, P159, P160) and (B) two
independent experiments in triplicate for each cell line exposure evaluated.
Figure 2.

SDF-1 message is modestly reduced in bone marrow stromal cells

following chemotherapy treatment. Total RNA was isolated from confluent stromal cells
that were treated with (A) 100µM VP-16 or (B) 1.0µM doxorubicin for 8-24 hours. “OneStep” RT-PCR was completed using 0.1µg total RNA isolated from untreated, VP-16
treated, and doxorubicin treated stromal cells. SDF-1 and actin specific PCR products
were separated on 1.5% ethidium bromide stained gels, and ratios were quantitated by
densitometric analysis. Negative controls, containing no RNA template, were included
for all samples (cell lines: Ped299, P156, P159, P160).
Figure 3.

Stromal cell capacity to support JM-1 migration is restored by rSDF-1

following treatment. (A) Confluent stromal cell layers were treated with 1.0µM or 100µM
VP-16, 0.1µM or 1.0µM doxorubicin, or left untreated for 24 hours. Cells were rinsed
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thoroughly and 350µl of Iscoves complete was placed in each well. Following 24 hours,
80,000-120,000 JM-1 cells were placed in the top chamber.

Following a 4.5-hour

incubation, JM-1 cells that had migrated to the lower chamber were enumerated and
percent chemotaxis relative to untreated stromal cells was determined. Negative and
positive control samples included medium only or 5ng/ml recombinant human SDF-1,
respectively, in the lower chamber. Mean percent migration is shown with SE. Data
shown represents 3 independent experiments (cell lines: Ped299, P156, P159, P160).
(B) Confluent stromal cell layers were treated with 1.0µM or 100µM VP-16, 0.1µM or
1.0µM doxorubicin, or left untreated for 24 hours. Stromal cells were rinsed thoroughly
and medium with 5ng/ml rSDF-1 protein was placed in each well. Following a 4.5-hour
incubation, JM-1 cells that had migrated to the lower chamber were enumerated and
percent chemotaxis was determined. Negative and positive control samples included
medium only or rSDF-1, respectively, in the lower chamber. JM-1 migration towards
medium only was less than 10% of that observed for medium plus 5ng/ml rSDF-1 in
each case (data not shown). Mean percent JM-1 chemotaxis is shown with SE. Data
shown represents 3 independent experiments (cell lines: Ped299, P159, P160).
Figure 4.

VP-16 treated stromal cells have sustained reductions in SDF-1 protein

production. Stromal cells were treated with VP-16 for up to 72 hours and allowed to
recover for up to 5 days following removal of drug.

ELISAs were completed to

quantitate SDF-1 protein level as described in Materials and Methods. All samples
were evaluated in triplicate. Mean ± SE, as % of control, are shown at each point. Data
represent 3 independent experiments.
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Figure 5.

Stromal cell ability to support JM-1 chemotaxis does not recover for up to

three days following removal of chemotherapy. Stromal cell layers were treated for up
to 72 hours with 100µM VP-16.

Following treatment, stromal cells were rinsed

thoroughly and 1ml of fresh medium was placed in each well for 72 hours. Following 72
hours of recovery, the supernatants were removed and replaced with fresh Iscoves
complete medium. Chemotaxis assays were completed 24 hours later using JM-1 cells.
All samples were evaluated in triplicate. Mean percent JM-1 chemotaxis is shown ± SE.
Data shown represent 3 independent experiments.
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Figure 1. VP-16 and doxorubicin reduce bone marrow stromal
cell SDF-1 protein expression
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Figure 2. SDF-1 message is modestly reduced in bone marrow
stromal cells following chemotherapy treatment
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Figure 3. Stromal cell capacity to support JM-1 migration is
restored by rSDF-1 following treatment
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Figure 4. VP-16 treated stromal cells have sustained reductions
in SDF-1 protein production
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Figure 5. Stromal cell ability to support JM-1 chemotaxis does not
recover for up to three days following removal of chemotherapy
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ABSTRACT
Bone marrow stromal cells are an essential regulatory component in the
hematopoietic microenvironment.

Regulation of hematopoietic cell development is

mediated, in part, through interaction of progenitor cells with stromal cell vascular cell
adhesion molecule-1 (VCAM-1). VCAM-1 expression has been shown to be primarily
driven by binding of NF-κB to two consensus binding sites in the promoter region. In
this study we show that down regulation of VCAM-1 by the chemotherapeutic agent
etoposide (VP-16) is associated with altered cellular localization of NF-κB.
We demonstrate that VCAM-1 was diminished at the transcriptional level
following stromal cell VP-16 treatment, without alteration of VCAM-1 stability. Culture of
bone marrow stromal cells in VP-16 resulted in reduced nuclear RelA (p65), a modest
increase in nuclear NF-κB1 (p50), and reduced NF-κB binding to its DNA consensus
sequence.

Total levels of the NF-κB inhibitor, Iκ-Bα, were reduced during VP-16

exposure. Following removal of VP-16 from culture, p65 and p50 nuclear profiles
approximated those of untreated stromal cells, and VCAM-1 protein expression was
restored.
The current study indicates NF-κB as a target molecule that is responsive to VP16 induced damage in bone marrow stromal cells. As the primary transcription factor
that promotes VCAM-1 expression, the observed changes in p65 and p50 cellular
localization during treatment have direct consequence for stromal cell function. The
myriad of genes regulated by NF-κB, including both adhesion molecules and cytokines
that contribute to stromal cell function, make chemotherapy induced disruption of NF-κB
biologically significant. Alterations in NF-κB activity may provide one measure by which
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the effects of aggressive treatment strategies on the bone marrow microenvironment
can be evaluated.
INTRODUCTION
The bone marrow microenvironment is the primary site of normal postnatal
hematopoiesis, and the location of hematopoietic recovery following chemotherapy or
irradiation induced injury to the immune system. Bone marrow stromal cells are critical
components of the marrow microenvironment that regulate hematopoietic cell survival,
proliferation, and differentiation {1-6}. As such, they insure appropriate development of
mature lymphoid and myeloid cells.

Therefore, appropriate stromal cell function is a

central regulatory component of hematopoiesis.
As treatments for many malignancies become increasingly aggressive, it has
become clear that targets for damage include not only malignant cells, and frequently their
normal counterparts, but also the supportive bone marrow stroma {1-6}. Stromal cell
damage is implicated by delays in hematopoietic recovery, even when healthy progenitor
cells are provided, as in the bone marrow transplantation setting {7-11}. While delays in
reconstitution of the hematopoietic system are an expected consequence of aggressive
chemotherapy, the extent to which a damaged microenvironment contributes to such
delays requires further investigation. We have previously reported, using an in vitro model,
that VP-16 treated bone marrow stromal cells have diminished capability to support
proliferation and survival of lymphoid and myeloid progenitor cells {7}. This altered support
capacity is associated with reduced VCAM-1 protein expression {12;13}. Altered capacity
to support hematopoietic cells was not due to initiation of stromal cell apoptosis. No
laddering of DNA was detected following treatment, and stromal cells proliferated following
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removal of VP-16 {7}. Other investigators have also noted reduced VCAM-1 expression
on bone marrow stromal cells derived from patients treated with a variety of
chemotherapeutic agents {12}. Interestingly, previous reports have indicated a specific
decrease in VCAM-1 expression in human umbilical vein endothelial cells following
exposure to topoisomerase II inhibitors, including VP-16 {13}.

These previous

observations, combined with the frequent use of VP-16 in several treatment regimens
{14;15} make it a clinically relevant drug for further investigation.
Several studies have demonstrated that physical interaction between stromal cells
and hematopoietic progenitors is essential during hematopoiesis {16-21}. Co-culture of
human hematopoietic progenitors with stromal cells separated by transwell membranes
resulted in reduced viability of progenitor cells compared to those in direct co-culture {4}.
VCAM-1 has been identified as a critical molecule that mediates adhesion of progenitors
to stromal cells in both murine and human in vitro models {20;22-27}. Murine in vivo
models have indicated that interaction of VLA-4 on immature progenitor cells with stromal
cell VCAM-1, engages signaling pathways essential to hematopoietic cell development
{28}. Stromal cell cultures established from patients treated with a variety of
chemotherapeutic regimens have diminished adhesion of immature B lineage progenitor
cells, reduced capacity to support expansion of this same population, and lower levels of
VCAM-1 than stromal cells from untreated control patients {12}. These combined
observations suggest that disrupted stromal cell VCAM-1 during chemotherapy may
contribute to delayed hematopoietic recovery following cessation of treatment.
It is well documented that transcription of VCAM-1 is regulated, in part, by binding
of NF-κB to consensus binding sites in the VCAM-1 promoter {29-31}. In some cell types,
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binding of homodimeric p65 has also been shown to enhance VCAM-1 transcription
{29;30}. While the contribution of NF-κB and/or p65 homodimers appears largely cell type
specific, a consistent model prevails in which p65 activates VCAM-1 transcription {30;32}.
Binding of the trans-activating factors Sp-1 and IRF-1 to their recognition sequences in
the VCAM-1 promoter further enhances NF-κB gene transcription {31;33}. In contrast to
p65, dramatic increases in level of p50, favoring the generation of p50 homodimers, has
been reported to repress VCAM-1 expression {30;31}.
NF-κB heterodimers can be retained in the cytoplasm by masking of the nuclear
localization signal. This is mediated primarily through interaction with inhibitory proteins
of the Iκ-B family {34;35}. Signals that result in degradation of IκB molecules reveals
the NF-κB nuclear localization signal, allowing transit to the nucleus and DNA binding.
Inhibition of NF-κB activity can be mediated by sequestering the active heterodimer in
the cytoplasm complexed with Iκ-B, or through displacement of p50/p65 heterodimers
by repressive p50 homodimers {30;31}.
NF-κB expression and cellular localization have been shown to respond to a
variety of stimuli including chemotherapy, radiation and cytokine stimulation {36-38}.
However, the response of NF-κB to chemotherapy in bone marrow stromal cells has not
been characterized. Data presented in the current study reveal altered NF-κB cellular
localization following exposure of stromal cells to VP-16, consistent with reduced
stromal cell VCAM-1. Diminished nuclear localization of NF-κB in bone marrow stromal
cells following VP-16 exposure may be central to the mechanism by which
chemotherapy disrupts the bone marrow microenvironment.
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MATERIALS AND METHODS
Establishment of fibroblastic bone marrow-derived stromal cell cultures.
Stromal cell cultures were initiated from 200µL of unfiltered human bone marrow
from consenting donors, with approval by the WVU Institutional Review Board, as
previously described {7}.
Chemotherapy treatment of bone marrow cells.
VP-16 was obtained at a stock concentration of 20mg/ml (Bristol-Myers Squibb,
Princeton, NJ) and diluted in culture medium to 100 µM prior to use to approximate
serum levels reported for patients on high dose therapy {15}. Stromal cells were grown
to confluence prior to treatment. For experiments that evaluated NF-κB recovery, cells
were treated with 100µM VP-16 for 3 hours, rinsed four times with fresh α-MEM, and
cultured for 24-72 hours in fresh media.
RNA isolation.
Total RNA was isolated from stromal cells using the Invitrogen S.N.A.P. Total
RNA Isolation kit (Invitrogen; Carlsbad, CA) following the recommendations of the
manufacturer. Pelleted stromal cells were lysed by centrifugation through QIAshredder
Spin Columns (QIAGEN Inc.; Santa Clarita, CA).

RNA was DNase treated and

quantitated at 260nm (Perkin-Elmer Lambda 5 UV/VIS Spectrophotometer; PE
Corporation; Norwalk, CN).
Polymerase Chain Reaction.
To evaluate changes in VCAM-1 mRNA following VP-16 treatment, semiquantitative PCR was performed.

The linear ranges of amplification for actin and

VCAM-1 were determined to be 25 and 30 cycles respectively. Amplification cycles
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included denaturation at 94oC for 30 seconds, primer annealing at 55oC for 1.5 minutes,
and extension at 72oC for 2 minutes and15seconds (Perkin-Elmer GeneAmp PCR
System 9600). cDNA’s were generated by random priming of 1µg total RNA. Actin
primer

sets

were:

5’-TGACGGGGTCACCCACACTGTGCCCATCTA-3’

CTAGAAGCATTTGCGGTGGA

CGATGGAGGG-3’(Stratagene;

0.4µg/reaction to generate an amplicon of 661 base pairs.
CATCCACAAAGCTGCAAGAA-3’

and

5’-GCCACCACTC

(0.5µg/reaction) generated a 563 base pair product.

La

Jolla,

and

5’-

CA) at

VCAM-1 primers: 5’-

ATCTCGATTT-3’

{39},

Controls that lacked reverse

transcriptase or cDNA template were included in all experiments. VCAM-1:actin ratios
were quantitated by EagleSight Version 3.21 (Stratagene) densitometric analysis.
RNase Protection Assay (RPA).
To evaluate VCAM-1 mRNA, RPA’s were performed using the RPAIII kit
according to the manufacturer’s protocol (Ambion, Austin, TX). Confluent stromal cell
layers were treated with 5µg/mL actinomycin D (Sigma Chemical Co.; St. Louis, MO)
with and without 100µM VP-16. 10µg of RNA from each sample were hybridized to
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labelled VCAM-1 and GAPDH-specific complementary RNA probes. Anti-sense
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PP-

RNA probes were generated using T7 RNA polymerase-directed synthesis from
RiboQuant DNA templates (PharMingen; San Diego, CA). Nucleic acids were treated
with RNase A & T1 to digest unhybridized sequences. RNA corresponding to VCAM-1
(288bp) and GAPDH (96bp) were visualized by exposure to Phospho-Imager cassettes
(Molecular Dynamics; Sunnyvale, CA). VCAM-1 band intensities were normalized to
GAPDH controls in each treatment group.
Intracellular protein staining.
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Bone marrow stromal cells were cultured on coverslips (Corning Inc.; Corning,
NY) for 24 hours prior to treatment with 100µM VP-16 for 3-6 hours.

Following

treatment, cells were fixed in methanol:acetone (1:1) for 20 minutes at room
temperature then rinsed in autoclaved PBS. Non-specific antibody binding was blocked
by incubation of stromal cells with PBS/5%BSA for 30 minutes at room temperature.
Cellular localization of p50 or p65 protein was evaluated by incubation of stromal
cells with 10µg rabbit anti-human p50 or p65 (Santa Cruz Biotechnology, Inc.; Santa
Cruz, CA) for 1 hour at room temperature. Coverslips were then rinsed in autoclaved
PBS and subsequently incubated with goat anti-rabbit IgG-FITC (Santa Cruz
Biotechnology). Fluoromount-G (Southern Biotechnology Associates, Inc.; Birmingham,
AL) was added and coverslips were inverted onto slides for evaluation by fluorescent
microscopy (Zeiss LSM 510, Germany).
Isolation of stromal cell nuclei.
Isolation of nuclear proteins was completed as described by Andrews, et al. {40}.
Briefly, 0.5x105-2.0x106 stromal cells were re-suspended in 400µL of 40C Buffer A
(10mM HEPES-KOH pH 7.9, 1.5mM MgCl2, 10mM KCl, 0.5mM DTT, 0.2mM PMSF).
Following incubation on ice for 10 minutes, samples were vortexed for 10 seconds and
pelleted to isolate nuclei. Nuclei were then resuspended in Buffer C (20mM HEPESKOH pH 7.9, 25% v/v Glycerol, 420mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 0.5mM
DTT, 0.2mM PMSF) and incubated on ice for 20 minutes. Following centrifugation to
remove debris, supernatants containing nuclear proteins were stored at -700C until use.
Protein concentrations were determined using the BCA Protein Assay kit (Pierce,
Rockford, IL).
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Western blot analysis.
Western blot analysis was performed following the method described by
Laemmli, et al. {41}. For evaluation of p65 or p50, nuclear proteins {10µg/lane} were
separated by SDS-PAGE and transferred to PVDF-Plus nylon membranes (MSI,
Westborough, MA). Membranes were probed with 0.5µg/ml polyclonal rabbit anti-human
p65 (Santa Cruz Biotechnology) or a 1:2000 dilution of polyclonal rabbit anti-human p50
(generously provided by Dr. Nancy Rice, National Cancer Institute, Frederick Cancer
Research and Development Center, Frederick, MD). Membranes were incubated with
goat anti-rabbit-HRP (Santa Cruz Biotechnology).

Bands were visualized by ECL

(Amersham International; Buckinghamshire, England).

Densitometric analysis using

Eagle Eye II (Stratagene) or Optimus (Optimus Corp.; Bothell, WA) was completed for
quantitation. Isotype matched controls were included for all experiments. Protein from
5x104 stromal cells was evaluated by PAGE to determine total IκBα protein expression.
Membranes were probed with 1.5 µg/ml monoclonal mouse anti-human IκBα (Santa
Cruz Biotechnology) followed by 1:2000 dilution of goat anti-mouse-HRP (Santa Cruz
Biotechnology) for visualization.
Membranes were re-probed with polyclonal rabbit anti-human TFIIF-RAP30
(0.5µg/ml, Santa Cruz Biotechnology) as an internal lane loading control. To establish
ratios of p65 to p50 subunits, protein levels were compared within individual nuclear
samples, and normalized to untreated controls set to 1.0.

Statistical analysis was

performed using the Dunnett’s test (SigmaStat Version 2.0 software, SPSS Inc.;
Chicago, IL).
Electrophoretic mobility shift assay (EMSA).
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To determine if VP-16 altered NF-κB binding to its consensus sequence, EMSA’s
were performed. NF-κB consensus oligonucleotides (Santa Cruz Biotechnology) were
end labeled with

32

P-γATP using “Ready!To!Go” T4 Polynucleotide Kinase (Pharmacia

Biotech; Piscataway, NJ).

Reactions included 2µg nuclear protein, 2µg poly dI:dC,

1mM spermidine, 1X Promega buffer (10mM HEPES (pH 7.9), 50mM KCl, 0.2mM
EDTA, 2.5mM DTT, 10% glycerol, and 0.05% NP-40). Supershifts were completed by
the addition of rabbit anti-p50 or p65 (kindly provided by Dr. Nancy Rice) to indicated
samples. Following incubation on ice for two hours, 50,000 CPM (0.05-0.20ng) labeled
NF-κB consensus probe was added to all reaction mixtures. A 30-fold excess (2.08.0ng) of unlabeled specific (NF-κB) or non-specific (NF-AT) probe was added to
indicated samples to evaluate binding specificity. Samples were then incubated at room
temperature 30 additional minutes.
Complexes were separated through 5% polyacrylamide/1X TGE gels which were
dried for 2.5 hours at 80oC with vacuum (Bio-Rad Model 583 gel dryer; Richmond, CA)
and exposed to BioMax MR-1 film overnight (Kodak; Rochester, NY). Relative band
intensities were determined using Eagle Eye II (Stratagene).
(E)-Capsaicin treatment of stromal cells.
To determine if reduced p65 in stromal cell nuclei was sufficient to reduce
VCAM-1 expression, confluent stromal cells were treated for 4 or 8 hours (4 hour
exposures on two consecutive days) with 200µM (E)-Capsaicin (Alexis Biochemicals;
San Diego, CA). (E)-Capsaicin has been previously shown to reduce nuclear p65 levels
{42}. Stromal cell VCAM-1 protein was evaluated 24 and 48 hours later by ELISA as
described above.
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VCAM-1 ELISA.
To determine whether stromal cell VCAM-1 protein expression is restored
following removal of VP-16 from culture, confluent stromal cells were treated with
100µM VP-16 for 24-72 hours. Following treatment, cells were trypsinized, rinsed three
times in medium, counted, and replated into 96-well plates (10,000 cells/well) to allow
recovery for up to 72 hours following the 24 hour VP-16 exposure, or up to 5 days
following 72 hour chemotherapy treatment. Mouse anti human-VCAM-1 (2µg/ml; Santa
Cruz Biotechnology) and a matched isotype IgG1 control (Southern Biotechnology
Associates; Birmingham, AL) were incubated on stromal cell layers at 370C for 1 hour.
Following incubation, layers were rinsed 5 times (PBS/0.5% Tween 20). Sheep anti
mouse–HRP (1µg/ml; Amersham Life Science; Piscataway, NJ) was then incubated on
stromal cell layers at 370C for 1 hour and rinsed as above.

The TMB Microwell

Peroxidase Substrate System (Kirkegaard & Perry Laboratories; Gaithersburg, MD) was
used for quantitation of VCAM-1 protein. Isotype matched controls were included for all
treatment groups to evaluate non-specific antibody binding.

RESULTS

VCAM-1 transcripts in VP-16 treated stromal cells.
To determine whether VP-16 reduced the amount of VCAM-1 transcripts in bone
marrow stromal cells, their relative abundance was evaluated following 4-24 hours of
100µM VP-16 treatment. At 4 hours, message levels were approximately 65% of
untreated control values, and the abundance of VCAM-1 transcripts continued to
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diminish out to 24 hours of exposure (Fig. 1A). Controls that lacked template or reverse
transcriptase did not yield any product (data not shown).
VCAM-1 message stability.
To determine if reduced levels of VCAM-1 message following treatment of bone
marrow stromal cells with VP-16 were due to altered stability in the presence of
chemotherapy, confluent stromal cells were treated with actinomycin-D or both
actinomycin-D and VP-16 as described.

Following 3-24 hours of treatment, no

significant differences were observed between the half-life of VCAM-1 specific
transcripts in the presence and absence of VP-16. The half-life of VCAM-1 transcripts
in both treatment groups was approximately 12 hours (Fig. 1B).
NF-κB subunit cellular localization in stromal cells exposed to VP-16.
Intracellular localization of p65 and p50 in treated and control stromal cells were
evaluated by fluorescent microscopy as described. Untreated stromal cells expressed a
significant level of nuclear p65, while nuclei of VP-16 treated bone marrow stromal cells
had diminished to undetectable nuclear p65 expression (Fig. 2). In contrast, modestly
increased nuclear expression of p50 was observed following treatment (Fig. 2).
To quantitate the changes in nuclear profiles of p65 and p50 in stromal cells
treated with VP-16, Western blot analysis was completed. Following treatment with VP16 for 30 minutes to 3 hours, consistent decreases in nuclear p65 (Fig. 3A) and slight
increases in p50 (Fig. 3B) were observed. Statistically significant decreases in nuclear
p65 protein were observed after 1.5 and 3 hours of VP-16 exposure (P<0.05).
NF-κB binding to a κB consensus sequence.
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To investigate whether VP-16 altered binding of NF-κB to its consensus site,
EMSAs were completed as described in Materials and Methods. DNA binding of NF-κB
was reduced to approximately 50% after 6 hours of VP-16 exposure compared to
untreated stromal cells (Fig 4). A single complex was observed that could be shifted
with antibody specific for p50 or p65. A 30 fold excess of unlabeled NF-κB
oligonucleotide reduced the NF-κB binding by approximately 80%, with negligible
reduction of binding observed by inclusion of 30 fold excess NF-AT oligonucleotide (Fig.
4).
Iκ-Bα expression in VP-16 treated stromal cells.
To determine if elevated Iκ-Bα was a potential mechanism by which p65 was
reduced in the nucleus of VP-16 treated stromal cells, total Iκ-Bα protein was evaluated
in treated and control stromal cells. A consistent reduction Iκ-Bα protein was observed
in VP-16 treated stromal cells (Fig. 5).
VCAM-1 expression in (E)-Capsaicin treated stromal cell VCAM-1.
To determine whether reduced nuclear p65 was sufficient to down regulate
VCAM-1 expression, confluent stromal cell layers were treated with (E)-Capsaicin as
described. VCAM-1 protein was consistently reduced following (E)-Capsaicin exposure
(Fig. 6).
Nuclear p65:p50 ratios following cessation of short term chemotherapy.
To evaluate recovery of nuclear p65 and p50 following short term exposure to
VP-16, stromal cells were treated with VP-16 for 3 hours, then allowed to recover for up
to 72 hours (Fig. 7A). After 24 hours of recovery, nuclear p65:p50 ratios began to
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approximate the untreated control ratio, and after 72 hours the p65:p50 ratio was
significantly higher than that immediately post-treatment (Tukey test; P<0.05).
VCAM-1 protein expression recovery following VP-16 treatment.
To determine if VCAM-1 protein recovered following treatment with VP-16,
stromal cell cultures were treated for 24-72 hours followed by 1-5 days recovery in fresh
medium. Following a short (24 hour) VP-16 exposure, VCAM-1 protein levels increased
at 24 hours, and reached control levels after 48 hours of recovery (Fig. 7B). In contrast,
when stromal cells were treated for 72 hours with VP-16, reduced VCAM-1 protein
expression was observed for up to 5 days (Fig. 7C).

DISCUSSION
We previously reported functional alteration of bone marrow stromal cells treated
with VP-16 {7}.

Specifically, treated stromal cells exposed to VP-16 had reduced

capacity to support survival and proliferation of lymphoid and myeloid progenitor cells,
and reduced levels of VCAM-1 protein expression {7}.

Because interaction of

hematopoietic progenitor cells with VCAM-1 on stromal cells has been shown to be
important for development of progenitor cells {21-23;28}, we investigated a potential
mechanism by which VP-16 exposure results in dysregulated VCAM-1 expression.
Consistent with our previous report of reduced VCAM-1 protein in stromal cells
treated with VP-16 {7}, VCAM-1 mRNA was reduced following treatment (Fig. 1A). This
observation suggests that VP-16 either reduced the stability of VCAM-1 mRNA, or
resulted in diminished transcription of VCAM-1 in stromal cells. The reduction in VCAM1 RNA in the presence of VP-16 was not due to altered stability (Fig. 1B).
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This

observation prompted investigation of transcription factors that potentially mediated
diminished expression.
We have previously reported that while VCAM-1 expression is reduced by
treatment of stromal cells with VP-16, fibronectin is not altered {7}, suggesting VP-16
modulation of transcription factors that bind to the VCAM-1 promoter and not
fibronectin. Two NF-κB consensus binding sites have been identified in the VCAM-1
promoter region {43} while fibronectin is activated primarily by Sp-1 binding {44;45}.
NF-κB or p65 homodimeric molecules have been reported to enhance transcriptional
activity of the VCAM-1 gene in a variety of systems through binding to these sites
{43;46-48}.
Evaluation of stromal cell nuclear profiles of p65 and p50 indicated reduced
levels of nuclear p65 following treatment with VP-16 (Fig. 2 and 3A). This observation is
consistent with reduced availability of p65 to maintain VCAM-1 transcription during VP16 exposure. Ratios of p65:p50 were not significantly different in whole cell lysates of
treated stromal cells compared to matched controls (data not shown).

These data

suggest that VP-16 primarily results in signals that alter cellular localization of NF-κB
subunits, but does not impact total expression levels of p65 or p50. One direct means
by which VP-16 may alter nuclear translocation of p65 is through physical interaction
that either masks the nuclear localization signal, or alters nuclear pore permeability.
However, while VP-16 has been shown to directly bind various proteins {49;50}, no
binding of 3H-VP-16 to immunoprecipitated stromal cell p65 was observed (data not
shown). To address the possibility that VP-16 masked the protein sites necessary for
antibody interaction, immunoprecipitations were completed with nuclear protein,
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unlabeled VP-16, and α-p65 antibody.

Subsequent Western blot analysis readily

detected p65 (data not shown).
The prototypic molecule reported to detain p65 in the cytoplasm is Iκ-Bα through
either increased expression or stability {34;35}. However, Iκ-Bα did not play an obvious
role in sequestering p65 in the cytoplasm of stromal cells following VP-16 exposure.
Total Iκ-Bα protein levels were diminished following treatment (Fig. 5). The reduction of
Iκ-Bα protein was consistent with previous reports of κB binding sites in the Iκ-Bα
promoter {35;51}.
The observation that Iκ-Bα did not play a clear role in retention of p65 in the
cytoplasm following VP-16 treatment did not rule out the possibility that another
inhibitory molecule may have enhanced expression following treatment with VP-16. To
investigate this possibility, levels of p100 and p105 proteins, which can also detain p65
in the cytoplasm, were evaluated as potential regulatory molecules that may respond to
chemotherapy exposure. No consistent increase in either protein was observed
following VP-16 exposure in three stromal cell lines examined (data not shown). In
combination, these observations suggest a mechanism, other than interaction of p65
with an obvious inhibitory protein, that accounts for reduced p65 levels in the nucleus
following treatment.

Alteration of the nuclear pore complex seems unlikely as p50

entrance to the nucleus was not disrupted in VP-16 treated stromal cells.
In contrast to p65, modest increases in nuclear p50 were noted in VP-16 treated
stromal cells (Fig. 2 and 3B). Homodimers of p50 have been previously reported to
repress VCAM-1 transcription in cells lines generated to over express p50 {30;31}.
However, p50 homodimer complexes were not discerned by EMSA in our model (Fig.

97

4).

Homodimeric p50 may have been present at a level below our sensitivity of

detection. However, a modest increase in stromal cell nuclear p50, combined with a
consistent decrease in nuclear p65 in cells treated with VP-16, results in a ratio less
conducive to NF-κB driven VCAM-1 expression.
Treatment of stromal cells layers with (E)-Capsaicin reduced VCAM-1 expression
at 24 and 48 hours (Fig. 6). We have previously determined that the half life of stromal
cell VCAM-1 is approximately 24 hours (unpublished data), providing the rationale for
evaluation of VCAM-1 protein 24 and 48 hours after disruption of nuclear p65 by (E)Capsaicin. This observation supports the premise that reduced nuclear p65 is sufficient
to diminish VCAM-1 expression, and suggests that chemotherapeutic agents that
modulate cellular localization of p65 potentially alter stromal cell VCAM-1 expression
through this mechanism.
The recovery of p65 and p50 nuclear levels to baseline following removal of VP16 following a 3 hour exposure suggests an absence of permanent damage to stromal
cells following short term exposure (Fig. 7A). In addition, restoration of VCAM-1 protein
expression following removal of drug occurred following 24 hour treatment (Fig. 7B), but
not following 72 VP-16 exposure (Fig. 7C). This observation suggests a potential link
between duration of drug exposure and severity of damage that may be as critical as
drug dose. We have previously reported that while VP-16 disrupted the ability of
confluent stromal cell layers to support hematopoiesis, it did not induce stromal cell
apoptosis, confirmed by an absence of DNA laddering or PI staining {7}. The inability of
VP-16 to initiate apoptosis in non-cycling confluent stromal cell cultures is in marked
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contrast to its ability to efficiently induce death in dividing cells. This suggests unique
NF-κB mediated signaling pathways in cycling versus quiescent cells.
The relevance of the current study may not be in designing strategies to prevent
damage to the microenvironment, but rather in understanding the kinetics of stromal cell
recovery following chemotherapy. Attempts at maintaining nuclear levels of p65 during
treatment to sustain VCAM-1 expression on stromal cells would likely prove detrimental.
NF-κB has been shown to be a critical component of the apoptotic pathway in various
model systems {37}, therefore, blocking translocation of p65 or p50 subunits in
response to chemotherapy would likely diminish the efficacy of treatment in many
circumstances
The rationale for investigating the response of NF-κB to chemotherapeutic
agents rests in its ability to regulate several stromal cell genes. In addition to altered
VCAM-1 expression, we have observed reduced transcription of stromal cell GM-CSF
(unpublished data) in VP-16 treated cells. Like VCAM-1, GM-CSF expression has been
shown to be regulated, in part, by NF-κB binding {52}. In combination, the appropriate
expression of stromal cell adhesion molecules and cytokines define the ability of the
microenvironment to support hematopoiesis. The response of stromal cell NF-κB to
specific chemotherapeutic agents may provide insight into mechanisms that contribute
to a disrupted bone marrow microenvironment, and the delayed hematopoietic recovery
that is associated with specific chemotherapeutic agents.
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FIGURE LEGENDS
Figure 1. VCAM-1 transcripts in bone marrow stromal cells treated with VP-16. (A) To
determine if VCAM-1 mRNA expression was altered by VP-16 treatment, semiquantitative PCR was performed as described in Materials and Methods. Actin and
VCAM-1 specific sequences were amplified from RNA isolated from untreated control
stromal cells and stroma treated for 4-24 hours with 100µM VP-16 as indicated. (B) To
evaluate VCAM-1 message stability, stromal cells were treated with 100µM VP-16 in the
presence of actinomycin-D as described in Materials and Methods. RNase protection
was completed to quantitate VCAM-1 specific RNA in untreated control stromal cell
layers in the presence of actinomycin-D, compared to those treated for up to 24 hours
with both VP-16 and actinomycin-D. Values shown are relative to control values set to
1.0.
Figure 2. Cellular localization of NF-κB p65 and p50 subunits following treatment of
bone marrow stromal cells with VP-16. The relative amount and cellular localization of
p50 or p65 protein in stromal cells treated with VP-16 for 3 hours (p65) or 6 hours (p50)
was determined by fluorescent microscopy as described in Materials and Methods.
Following treatment, stromal cells were fixed in methanol:acetone and p65 or p50
protein detected by incubation with 200µg/mL rabbit anti-human p50 or p65 (Santa Cruz
Biotechnology, Inc.; Santa Cruz, CA). Data shown are representative of 3 stromal cell
lines evaluated.
Figure 3. Nuclear p65 and p50 protein in stromal cells following treatment with VP-16.
To quantitate changes in nuclear levels of p65 and p50 in stromal cells exposed to VP16, Western blot analysis of nuclear proteins was completed as described in Materials
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and Methods. Stromal cells were treated with 100µM VP-16 for 30 minutes to 3 hours
as indicated, and nuclei isolated as previously described for protein analysis. Nuclear
p65 (panel A) and nuclear p50 (panel B) were evaluated by Western blot analysis. A
representative control (RAP 30) is shown for one experiment. Data from 4 independent
experiments evaluating nuclear p65, and 5 independent experiments evaluating nuclear
p50 expression are normalized to untreated control values are summarized in panel C.
Figure 4. NF-κB binding to its consensus sequence in VP-16 treated stromal cells. To
determine if VP-16 exposure resulted in alterations of NF-κB binding to its consensus
sequence, EMSA’s were performed as described in Materials and Methods.
Densitometric analysis was completed to quantitate relative band intensities.
Figure 5. Iκ-Bα protein expression in stromal cells exposed to VP-16. (A) To evaluate
total Iκ-Bα protein levels in stromal cells following VP-16 exposure, confluent stromal
cell layers were treated for 30 minutes to 3 hours and Western blot analysis completed.
(B) Densitometric analysis of 3 representative experiments are shown (SEM). Reduced
IκB-α protein was observed at all time points evaluated.
Figure 6. VCAM-1 expression in (E)-Capsaicin treated stromal cells. Confluent bone
marrow stromal cells were exposed to a single 4 hour treatment of Capsaicin, or to 4
hour treatments on two consecutive days, and VCAM-1 ELISA completed at 24 and 48
hours respectively.

Isotype matched control binding indicative of non-specific

background was subtracted from each sample. Data from two independent stromal cell
lines, P154 (solid bar) and P155 (hatched bar), are shown with SEM.
Figure 7. Nuclear p65 and p50, and VCAM-1 protein expression return to baseline
levels following removal of chemotherapy. To determine if nuclear profiles of p65 and
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p50 returned to baseline following termination of VP-16 exposure, confluent stromal cell
cultures were treated for 3 hours with 100µM VP-16, then thoroughly rinsed with media
and allowed to recover for up to 72 hours as described in Materials and Methods.
Subsequently, nuclear p65 and p50 protein was evaluated by Western blot analysis and
densitometry completed (panel A).

Values are shown with SEM.

(B) Stromal cell

VCAM-1 protein following removal of VP-16 from cultures was evaluated by ELISA as
described in Materials and Methods. Confluent layers were treated for 24 hours, and
allowed to recover for up to 60 hours in fresh medium. Isotype matched controls are
shown for each sample.

Values are shown with SEM.

(C) VCAM-1 protein was

evaluated by ELISA following up to 72 hours of VP-16 exposure, followed by 1-5 days
recovery in fresh medium as described in Materials and Methods. Values from two
different human stromal cell lines, P154 (solid bar) and P155 (hatched bar) are shown
with SEM. Isotype matched control antibody binding was subtracted from each value.
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Figure 1. VCAM-1 transcripts in bone marrow stromal cells
treated with VP-16
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Figure 3. Nuclear p65 and p50 protein in stromal cells following
treatment with VP-16
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Figure 7. Nuclear p65 and p50, and VCAM-1 protein expression
return to baseline levels following removal of chemotherapy
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ABSTRACT

VCAM-1 protein expression in the bone marrow microenvironment on fibroblastic
stromal cells is critical for normal B-cell lymphopoiesis. Diminished interaction between
VLA-4 on immature B-cells and VCAM-1 on stromal cells results in dysregulated Blymphopoiesis. In the current study, murine stromal cells were transfected with human
VCAM-1 cDNA expressed from a constitutive promoter. Stromal cells transfected with
human VCAM-1 cDNA or β-galactosidase support early B-cell expansion and survival
equally well.

However hVCAM-1 lines are quantitatively different from the β-

galactosidase expressing vector control lines.

In coculture with immature B-cells,

increased numbers of proB cells adhere to hVCAM-1 expressing stromal cells
compared to vector control cell lines. ProB cells on hVCAM-1 expressing stromal cells
maintained a higher viability compared to vector contol cell lines. And, murine stromal
cells

maintain

expression

of

human

VCAM-1

following

exposure

to

the

chemotherapeutic agent etoposide (VP-16) while endogenous murine VCAM-1
decreased after treatment.

These stromal cell lines will be useful in studies that

evaluate the role of VCAM-1 maintenance following chemotherapy in hematopoietic
restoration.
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INTRODUCTION
The

critical

role

of

Vascular

Cell

Adhesion

Molecule-1

(VCAM-1)

in

hematopoiesis has been well established through both in vitro and in vivo models (1-8).
VCAM-1, a surface bound stromal cell adhesion molecule, is an essential component of
stromal cell support of hematopoietic stem and progenitor cells (9-16). An essential role
of VCAM-1 is contributing to retention of VLA-4 positive hematopoietic progenitor cells
in the bone marrow. Injection of anti-VCAM-1 antibody into mice disrupts stromal and
hematopoietic progenitor cell associations and results in disrupted B-lymphopoiesis
(16). In addition, hematopoietic progenitor cells are mobilized in primates following antiVLA-4 antibody treatment (11).
Bone marrow stromal cell VCAM-1 protein levels are altered by local marrow
cytokine influences, with reduced VCAM-1 protein expression linked to alterations of
immature B-cells adherence to bone marrow stromal cells. Disrupted adhesion leads to
dysregulation of early B-cell development (17).

Further studies on ex vivo expanded

bone marrow stromal cells from patients receiving various conditioning regiments in
preparation for bone marrow transplantation demonstrated reduced VCAM-1 protein
expression and diminished capacity to support normal B-cell precursor growth in vitro
(8). These observations suggest an essential role of VCAM-1 in the development of
progenitor cells committed to the B cell lineage.
We have previously reported reductions of surface VCAM-1 protein following
human or murine bone marrow stromal cell exposure to etoposide in vitro. (18).
Subsequently, we demonstrated that reduced stromal cell VCAM-1 protein following
exposure to etoposide was due to alterations in vcam-1 gene transcription reflected by
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reduced numbers of VCAM-1 transcripts (19). Two key studies, one ex vivo (8) and one
in vitro (18), suggest that exposure to specific classes of chemotherapeutic drugs alter
the functional capacity of stromal cells to support early B-cell development in a VCAM-1
specific manner. These studies support the premise that VCAM-1 dysregulation may
contribute to the clinical observation of delayed B-cell reconstitution following dose
escalated chemotherapy and bone marrow transplantation (8;20;21). Together, these
data suggest that stromal cells expressing VCAM-1 from a constitutive promoter have
the potential to partially restore functional capacity of chemotherapy treated bone
marrow to support immature B-cell development.
In this study, we generated and characterized murine stromal cell lines that
constitutively express human VCAM-1 or β-galactosidase from the mammalian
housekeeping gene promoter, EF1α. These cell lines maintain surface human VCAM-1
(or intracellular β-galactosidase) following etoposide exposure, while endogenous
murine VCAM-1 is diminished. A higher percentage of pro-B cells were bound when
cocultured with human VCAM-1 expressing lines as compared to β-galacatosidase
vector control lines. In addition, IL-7 dependent pro-B cells maintained significantly
higher viabilities on human VCAM-1 cell lines in the absence of IL-7 than when
cocultured on vector control stromal cells.

These observations suggest that

maintenance of VCAM-1 expression on bone marrow stromal cells following high dose
chemotherapy may facilitate B-cell recovery through enhanced interactions with
immature B-cells. In addition, these data indicate that VLA-4 occupancy may delay the
onset of apoptosis, which is characteristic of proB Cell IL-7 deprivation.
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MATERIALS & METHODS
Cell lines
Stromal Cells:
The cloned murine stromal cell line, S-10 (22), was kindly provided by Dr.
Kenneth Landreth (West Virginia University, WV) with the permission of Dr. Kenneth
Dorshkind (University of California at Los Angeles, CA). S-10 stromal cell lines were
maintained in Iscove's medium supplemented with 5% Fetal Bovine Serum (Summit; Ft.
Collins, CO) , 2mM L-Glutamine (GibcoBRL; Rockville, MD), 100U/ml Penicillin (Sigma;
St. Louis, MO), 100µg/ml Streptomycin (Sigma), 5x10-5M β-mercaptoethanol (Sigma).
Human stromal cells were initiated from consenting donor’s bone marrow, with
approval by the West Virginia University Institutional Review Board, as previously
described (18). All stromal cell primary cultures were initiated from donors with no
previous chemotherapy exposure. Human derived stromal cells were maintained in
media identical to that of murine lines with the exception of FBS increased to 10%.
Pro-B cells:
C1.92, a non-transformed murine fetal liver (d14) derived pro-B cell line (23), was
kindly provided by Dr. Kenneth Landreth (West Virginia University, WV).

C1.92 is

stromal cell dependent and requires exogenous recombinant IL-7 (rIL-7) for sustained
survival and proliferation.
Human VCAM-1 and β-galactosidase transfected cell lines
The murine S-10 cell line was stably transfected with pTRACERTM-EF/Bsd-LacZ
(pTlacZ) (expression of β-galactosidase from EF-1α promoter) or pTRACERTM-EF/BsdA-hVCAM-1 (pTaV) (expression of human VCAM-1 from EF-1α promoter) (Invitrogen;
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Carlsbad, CA) (Figure 1). The pTaV vector was generated as follows: Human VCAM-1
(hVCAM-1) cDNA (Ingenius; Madison, WI) was excised from pCDM8 by restriction with
Xho-I. The hVCAM-1 cDNA fragment was previously subcloned into the pIRES2-EGFP
(pIE) (Clontech; Palo Alto, CA) multiple cloning site (MCS) at the Xho-I specific
restriction site. The entire MCS of pIRES2-EGFP was then subcloned into the Nco-I
site of pTRACER-EF/Bsd-A (pTa). The pIE MCS fragment was first circularized and
then cut with Eco-RI.

This fragment was then inserted into the pTa MCS Eco-R1

restriction site. The hVCAM-1 cDNA was transferred from the pIRES-EGFP-hVCAM-1
plasmid to the pTRACER-EF/Bsd-A-pIE-MCS plasmid via flanking Nhe-I (5’) and Sma-I
(3’) restriction sites. Appropriate orientation was confirmed by subsequent restriction
analysis.

S-10pTlacZ or S-10pTaV transfected cells that demonstrated blasticidin

resistance at 25µg/ml were used to isolate approximately 50 clones by limiting dilution.

β-galactosidase assay
In situ β-gal staining assay was performed as outlined in the Life Technologies
(Promega) “Guide to Eukaryotic Transfections with Cationic Lipid Reagents” booklet
(http://www.lifetech.com/searchaction2.cfm?cfid=408984&cftoken=44455543).

Briefly,

cells were fixed in 1X Dulbecco’s PBS (D-PBS) containing 2% formaldehyde and 0.05%
glutaraldehyde for 5 minutes, rinsed twice with 1X D-PBS, then stained overnight at
37oC in staining solution. Staining solution consisted of 1X D-PBS with 5mM potassium
ferricyanide, 5mM potassium ferrocyanide, 2mM MgCl2, and 1 mg/ml of X-gal
(Promega; Madison, WI). Cells were then rinsed in D-PBS and qualitatively evaluated
for β-gal staining. Cloned lines were scored from one to five based both on pace of
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color development and final color intensity. The two clones scoring the highest in β-gal
expression were primarily used in the current study and are designated C5 and C54.
Flow cytometry
Confluent stromal cell monolayers were harvested by trypsinization. Each 55cm2 plate
was divided into two samples for VCAM-1 and matched isotype antibody staining.
Samples were rinsed in 1X PBS/3% BSA, centrifuged and resuspended with 1µg of
mouse IgG1 α-human VCAM-1 (PharMingen; San Diego, CA) or rat IgG2a α-mouse
VCAM-1 (PharMingen) in 200 µL of 1X PBS/3% BSA.
included

nonimmune

mouse

IgG1

(Southern

Matched isotype controls

Biotechnology

Associates,

Inc.;

Birmingham, AL) and rat IgG2a antibodies (PharMingen). Goat α-mouse IgG1 – RPE
(Southern Biotechnology Associates, Inc.) and goat α-rat IgM/IgG – RPE (Southern
Biotechnology Associates, Inc.), were used at 1µg / 200µL of 1X PBS with 3% BSA
respectively for detection. Flow cytometric analysis was performed using FACScan and
CellQuest v. 3.1f software (Becton Dickinson, San Jose, CA).
Enzyme-Linked Immunosorbent Assay (ELISA)
Confluent stromal cell layers were treated with up to 100µM VP-16 for 48 hours in 96well tissue culture dishes (Falcon; Franklin Lakes, NJ). Prior to ELISA assay, all wells
were rinsed with isotonic phosphate buffered saline (1X PBS) and fixed for 20 minutes
at room temperature in 2% paraformaldehyde. Cells were rinsed twice with 1X PBS
and then incubated with 100mM glycine in PBS for 5 minutes. Further rinses were
carried out using 1X PBS/0.05% tween-20 (Sigma).

Cells were rinsed twice and

incubated with 0.2µg/100µl of primary or isotype matched antibodies at 37oC for 1 hour
(same antibodies as used for FACS analysis above). Following incubation, cells were
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rinsed five times with 1X PBS/0.05% tween-20 and 1µg/ml of appropriate secondary
antibody, sheep α mouse IgG – HRP (Amersham Pharmacia Biotech; Piscataway, NJ)
or goat α rat IgG – HRP (Southern Biotechnology Associates, Inc.) was added. After 1
hour, cells were again rinsed five times and colorometric quantitation was carried out
using the TMB Microwell Peroxidase Substrate System following the manufacturer’s
recommendation (Kirkegaard & Perry Laboratories; Gaithersburg, MD).

Wells were

read at 450nm using a µQuant Universal Microplate Spectrophotometer (Bio-Tek
Instruments, Inc.; Winooski, VT). The two clones scoring the highest in human VCAM-1
expression were primarily used in the current study and are designated V31 and V49.
Coculture of pro-B cells on C54 and V49 stromal cells
Four wells each of C54 and V49 were approximately 80% confluent at day 0
when 2x105 C1.92 cells in 1 ml of medium containing 25 U/ml recombinant mouse IL-7
(rIL-7) was added to each well. Established cocultures were harvested with trypsin after
1, 2, and 3 days of incubation. At day 2, additional IL-7 in 1 ml was added to each of
the day 3 wells.

C1.92 cells were counted based on easily distinguishable

morphological differences. Viability was determined by trypan blue exclusion.
For analysis of C1.92 on C54 or V49 in the absence of the exogenous growth
factor rIL-7, the experiments described above were repeated in medium alone. C1.92
cells were collected and rinsed at day 0 and resuspended in medium without rIL-7 prior
to starting assays.
Chemotherapeutic agents
VP-16 (Sigma) was mixed at a stock concentration of 20mg/ml (100mg VP-16,
650mg polyethylene glycol 300, 80mg Tween 80 (ultra pure), 30.5% ethanol, 2mg citric
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acid, 30mg benzyl alcohol) and diluted to 100 µM in culture medium immediately prior to
use. We have previously determined that matched vehicle doses do not impact on
murine or human VCAM-1 surface expression (data not shown). 100µM VP-16 was
chosen to approximate serum levels reported for patients on high dose therapy (24).
VP-16 stock solutions were stored at -80oC and diluted immediately prior to use.
RNA isolation
Total RNA was isolated from untreated confluent stromal cells using the S.N.A.P. Total
RNA Isolation kit following the recommendation of the manufacturer (Invitrogen;
Carlsbad, CA). Pelleted stromal cells were lysed by centrifugation through QIAshredder
Spin Columns (QIAGEN Inc.; Santa Clarita, CA).

RNA was DNase treated and

quantitated at 260nm (GENESYS-10UV; Spectronic Unicam; Rochester, NY).
Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR)
To evaluate human VCAM-1 and murine VCAM-1 RNA levels, “One-Step” RT-PCR
(Qiagen Inc.; Valencia, CA) was completed using RNA isolated from untreated or VP-16
treated stromal cells. Murine specific VCAM-1 primers were: 5’-CAA CGA TCT CTG
TAC ATC CC-3’ and 5’-AGA GGC TGT ACA CTC TGC CT-3’ (Stratagene; La Jolla,
CA). Primers were used at 0.08 µg/reaction to generate an amplicon of 839 base pairs
(25). Human specific VCAM-1 primers were: 5’-CAT CCA CAA AGC TGC AAG AA-3’
and 5’-GCC ACC ACT CAT CTC GAT TT-3’ (Stratagene; La Jolla, CA). Human VCAM1 specific primers were used at 0.08 µg/reaction to generate an amplicon of 563 base
pairs (26). Reverse transcription (RT) was completed at 50oC for 30min followed by an
RT deactivation cycle at 95oC for 15min. PCR amplification consisted of 30 cycles at
94o-30sec, 55o-1min/15sec, 72o-2min/15sec (Perkin-Elmer GeneAmp PCR System
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9600).

Samples included 0.1µg of total RNA isolated from treated and untreated

stromal cells as indicated above. As a negative control, samples that lacked RNA were
included in all experiments.
Chemotaxis assay
Migration of the CXCR-4+ cell line C1.92 toward medium alone or toward SDF-1 across
stromal cell layers of C54 or V49 was determined using 5µm pore/6.5mm diameter
tissue culture treated transwells (Corning, Inc.; Corning, NY). Stromal cell layers were
grown overnight on the transwell membranes to approximately 80% confluence.
Stromal cells were rinsed with fresh medium and 350µl of Iscove's medium was placed
in the bottom of each well. Stromal cells on transwell membranes were placed into
each well and 1.5x105 CXCR-4+ C1.92 cells in 150µl Iscove's medium were placed in
the top chamber. C1.92 chemotaxis toward medium alone, 10ng/ml or 100ng/ml of
recombinant human SDF-1 was measured. Transwells were incubated at 37o C for 3.0
hours. Cells migrating to the lower chamber were enumerated. C1.92 chemotaxis was
determined as percent of total input cell number. Control samples included medium
only in the lower chamber to evaluate spontaneous migration, and SDF-1 gradient wells
containing 100ng/ml recombinant human SDF-1 (rSDF-1) in the lower chamber.
Control wells were evaluated both in the presence and absence of stromal cell transwell
layers.
Binding assay
Pro-B cell binding to stromal cells on transwell filters was evaluated following
completion of chemotaxis evaluation. Transwells, following completion of chemotaxis
assays, were rinsed three times with fresh medium and then trypsinized to determine
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the percentage of bound C1.92 cells to the stromal cell/membrane layers.

Control

samples included medium only in the lower chamber to evaluate spontaneous
migration, and SDF-1 gradient wells included up to 100ng/ml recombinant human SDF1 (rSDF-1) in the lower chamber.

Statistical analysis
Statistical analysis was performed using One Way Analysis of Variance and Tukey Test
to detect differences among means (SigmaStat Version 2.0 software, SPSS Inc.;
Chicago, IL). All statistical comparisons represent treated samples as compared to
control levels, or comparison of C54 to V49 stromal cells where specifically indicated.

RESULTS
Stable transfection of murine S-10 stromal cells with human VCAM-1 and βgalactosidase.
The S-10 murine stromal cell line was transfected with either pTaV or pTlacZ
(see materials and methods). S-10pTlacZ (β-gal+) lines were designated “C” (for vector
Control line) followed by a corresponding clone number (e.g. C3, C5, C17, C27, C43,
C48, C54, C64, and C73). Nine β-gal+ control cell lines were qualitatively graded for the
kinetics and intensity of in situ β-gal staining (Table 1). C5 and C54 demonstrated the
highest relative β-gal expression compared to other clones.
S-10pTaV (hVCAM-1+) lines were designated “V” (for human VCAM-1 line)
followed by a corresponding clone number (e.g. V13, V18, V31 and V49).

V13

demonstrated a transformed phenotype suggested by loss of growth contact inhibition
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and was not used in further studies. The remaining three lines, V18, V31 and V49,
maintained an S-10 phenotype with contact inhibition and expressed human VCAM-1
protein determined by FACS analysis (Figure 2a-c).

The negative controls, vector

control cell lines C5 and C54, were both found to be negative for human VCAM-1
expression (Figure 2d-e). C54 and V49 were predominately used in further experiments
as they express the highest levels of β-galactosidase and human VCAM-1 respectively,
and had similar surface levels of endogenous murine VCAM-1 (Figure 3a-b).
Control cell lines, C5 and C54, and hVCAM-1+ cell lines, V18 and V49, were
evaluated for expression of human and murine VCAM-1 message. Primary human
stromal cell lines P160 and Ped300 as well as primary Balb/c murine stromal cells
(parental strain of S-10) were included as human and murine control cell lines. All
murine lines expressed mVCAM-1 message and only human control and hVCAM-1+
murine lines expressed hVCAM-1 RNA (Figure 4).

C54 and V49 support expansion and survival of the stromal cell-dependent pro-B
cell clone, C1.92 equally.
The β-gal+ control cell line C54 and the human VCAM-1+ line V49 were
compared for their ability to support pro-B cell expansion and survival. No statistical
difference in the ability of C54 or V49 to support C1.92 survival (>95% at each time
point) or expansion (2x105 to >5x106 by day three) was observed at any time point
(Figure 5).

Chemotaxis across C54 stromal cell layers is elevated compared to V49
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In vitro chemotaxis of C1.92 was compared between stromal cell layers of C54
and V49 (see materials and methods).

After three hours, chemotaxis across

C54/membrane transwells was 11.2%, 13.8%, and 20.2% toward medium, 10ng/ml, and
100ng/ml rSDF-1 respectively (Figure 6a).

Chemotaxis across V49 stromal cell

transwells was significantly lower at 1.4%, 4.5%, and 18.2% toward medium and
10ng/ml rSDF-1 (Figure 6b). Controls included, C1.92 chemotaxis towards 100ng/ml
SDF-1 which was 53.04±5.45%. Consistent with previous experiments, chemotaxis of
C1.92 in the absence of SDF-1 was negligible unless stromal cell layers were present.

C1.92 binding to V49 stromal cells is enhanced compared to the C54 vector
control line.
To determine whether differences in C1.92 adhesion to C54 and V49 exist,
binding assays were performed (see materials and methods). Following chemotaxis
assays, the transwell membranes were harvested and the number of stromal cell bound
C1.92 cells measured. The percentage of C1.92 bound to the membrane/C54 was
16.2% and 7.0% in the medium and 100ng/ml wells respectively, while 46.0% and
31.8% were observed in membrane/V49 wells (Figure 6b). Less than 1% of the pro-B
cells were associated with the membrane in matched transwells lacking stromal cell
layers.

Human VCAM-1 protein expression is maintained on V49 following exposure to
100µM VP-16.
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Reduced VCAM-1 protein and no changes in fibronectin protein were observed
when stromal cell lines C54 and V49 were exposed to VP-16 for up to 48 hours (Figure
7a). Additionally, human and murine VCAM-1 protein levels on C54 and V49 following
exposure to 50µM and 100µM VP-16 were evaluated. Endogenous murine VCAM-1
protein decreased on both C5 and V49 cells following treatment, but human VCAM-1
protein was maintained on V49 following exposure (Figure 7b).

V49 supports enhanced survival of the stromal cell and IL-7 dependent pro-B cell
clone C1.92 in the absence of exogenous growth factor.
No expansion of C1.92 cells was observed when cocultured with V49 in the
absence of exogenous rIL-7. However, coculture with V49 stromal cells resulted in
significantly higher maintenance of C1.92 viability compared to C54 cell cocultures
(Figure 8). C1.92 cell viability on V49 at day 3 was 90.5% while C1.92 viability on C54
at day 3 was only 65.4% (P<0.001).

Matched controls containing rIL-7 had C1.92

viabilities of 98.9% on V49 and 98.1% on C54 at day 3.

Unlike cocultures in the

absence of rIL-7, those with added rIL-7 expanded significantly (Figures 5 and 8).

DISCUSSION
We have generated and characterized murine marrow stromal cell lines that
constitutively express human VCAM-1 or β-galactosidase protein. These lines were
derived from the previously characterized parental cell line S-10 (22).

Both β-

galactosidase and hVCAM-1 lines sustain vector specific gene expression for greater
than 6 months in culture in the absence of selective media (Figures 2 and 4), maintain
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marrow stromal cell phenotype including contact growth inhibition, and exhibit similar
functional capacities in the support of the stromal cell dependent progenitor cell line
C1.92 (Figure 5).

Additionally, human VCAM-1 expressing lines demonstrated

increased progenitor cell binding capacity (Figure 6b) and supported enhanced viability
of pro-B cells in the absence of exogenous IL-7 (Figure 8).
Previously, Gibson, et al. has shown that human stromal cell VCAM-1 protein is
diminished following exposure to 100µM VP-16 (18).

In that study, no changes in

another adhesion molecule, fibronectin, were observed (18). In additional studies, we
demonstrated that down regulation of bone marrow stromal cell VCAM-1 protein
correlated with VP-16 induced loss of NF-κB nuclear localization and reduced VCAM-1
gene expression (19). These data underlie the hypothesis that maintenance of VCAM-1
gene expression and protein levels could be maintained in cell lines expressing the
VCAM-1 gene from a constitutive promoter that was not regulated by NF-κB. We now
show that stromal cell lines that constitutively express hVCAM-1, from a non-NF-κB
specific promoter, maintain baseline levels of protein expression following exposure to
VP-16 (Figure 7b). Interestingly, high levels of VCAM-1 availability delayed the onset of
apoptosis of the proB cell clone C1.92 in coculture in the absence of exogenous rIL-7
(Figure 8).
In the correct microenvironment, these cell lines may lead to new treatment
strategies involving ablative chemotherapy and bone marrow transplantation.

As

chemotherapy doses escalate to achieve maximal tumor cell death, stromal cell
damage is expected (8;27-31).

Several recent studies have demonstrated that co-

infusion or replacement of damaged cells with healthy stromal cells in conjunction with
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hematopoietic cells leads to enhanced hematopoietic recoveries following bone marrow
transplantation (32;33).

In the context of stromal cell replacement following ablative

chemotherapy, stromal cells engineered to express specific hematopoietic growth
factors or adhesion molecules may enhance stem cell maintenance and engraftment if
established in correct microenvironments. Additionally, healthy stromal cells may enrich
hematopoietic stem and progenitor cell homing, and restore robust B-cell development.
As such, VCAM-1 engineered stromal cell lines may prove useful in therapeutic
procedures during high-dose chemotherapy treatment strategies for advanced
metastatic cancers.
Although there have been several studies that suggest higher levels of stromal
cell VCAM-1 in concert with other stromal cell factors such as SCF and IL-6 correlate
with enhanced support of hematopoiesis, upregulated VCAM-1 alone has not been
evaluated (17;34).

Other studies have demonstrated that diminished stromal cell

VCAM-1 protein or blocking antibodies to VCAM-1 are associated with decreased
stromal cell support of hematopoiesis and stem cell homing (8;11;35-37).

Unlike

models of diminished VCAM-1 availability or enhanced VCAM-1 in conjunction with
other stromal cell derived factors, our stromal cell lines will allow us to characterize the
individual impact of enhanced stromal cell VCAM-1 in hematopoiesis and stem cell
homing in vitro.

These studies will establish a foundation for investigating the

therapeutic potential of enhanced bone marrow VCAM-1 expression preceding bone
marrow transplantation.
Furthermore, human VCAM-1 expressing murine stromal cell lines will enable us
to determine the specific impact that reductions in VCAM-1 protein on chemotherapy
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pretreated stromal cells has on the ability of these lines to efficiently support
hematopoiesis.

Additionally, these cell lines may prove useful in assessment of

immune system recognition of these lines in vivo (murine models) in the context of
xenoprotein expression viability (i.e. hVCAM-1) in host murine derived cells lines. In
contrast to enhanced hematopoietic recovery, evaluation of enhanced stromal cell
VCAM-1 expression and its contribution to protection of leukemia cells in the bone
marrow can now be further explored as well (38;39).
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FIGURE LEGENDS

Table 1. Qualitative expression of β-galactosidase in vector control cell lines (C3, C5,
C17, C27, C43, C48, C54, C64, and C73). β-gal assays were performed as described
in the materials and methods. Each cell line was graded from one (lowest) to five
(highest) based on both kinetics and final β-gal blue intensities.

Figure 1. Mammalian expression vector maps. β-galactosidase control expression
vector: pTRACERTM-EF/Bsd-LacZ (pTlacZ) and human-VCAM-1 expression vector:
pTRACERTM-EF/Bsd-A-hVCAM-1 (pTaV) [Invitrogen; Carlsbad, CA]

Figure 2. Human VCAM-1 (hVCAM-1) expression on selected hVCAM-1+ and β-gal+
cell lines.

A human VCAM-1 specific monoclonal antibody was used to evaluate

hVCAM-1 expression on hVCAM-1 lines (a) V18 (b) V31 (c) V49 and on vector control
lines (d) C5 (e) C54. Expression of hVCAM-1 was observed on all hVCAM-1 lines (a-c)
while no expression was detected on vector control lines (d-e). Isotype controls in each
figure are solid.

Figure 3. Murine VCAM-1 (mVCAM-1) expression on representative cell lines, C54 and
V49. A murine VCAM-1 specific monoclonal antibody was used to evaluate mVCAM-1
expression on the (a) β-gal+ cell line C54 and (b) the hVCAM-1+ cell line V49. Similar
levels of murine VCAM-1 was observed on each cell line.
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Figure 4. Human and murine VCAM-1 RNA expression in multiple cell lines. RT-PCR
analysis using human or murine specific primers demonstrated that all murine stromal
cell lines (Balb/c primary, S-10, C5, C54, V18, and V49) express mVCAM-1 messenger
RNA while only human (P160 primary and Ped300 primary) and hVCAM-1 murine cell
lines (V18 and V49) express hVCAM-1 messenger RNA. No template (N.T.) lanes
represent negative controls without RNA in the RT-PCR sample.

Figure 5. Expansion of the stromal cell-dependent pro-B cell line C1.92 on C54 or V49.
Similar stromal cell capacity to support C1.92 expansion or survival (>95% at each time
point, D.N.S.) was observed between the vector control cell line C54 and hVCAM-1+ cell
line V49. No statistical difference was found at any time point between C54 and V49
cocultures in total C1.92 cell number. 25 U/ml of rIL-7 was added to co-cultures at days
0 (all wells) and 2 (day 3 wells only).

Data representative of 3 independent

experiments.

Figure 6. Pro-B cell clone C1.92 (a) chemotaxis and (b) binding in modified chemotaxis
assays with C54 or V49 established at approximately 80% confluence on transwell
membranes. (a) Percent chemotaxis of C1.92 across C54 or V49 stromal cells grown
on 5µm pore membranes. Enhanced migration/passage of C1.92 across the stromal
cell:membrane layers was observed for C54 over V49 after 3 hours, and similar
chemotaxis levels were seen when 100ng/ml of rSDF-1 was in the lower chamber. (b)
Percent of stromal cells bound to the stromal cell:membrane following chemotaxis
assay (3 hours).

After the chemotaxis assay, transwells were rinsed 3x with fresh
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medium, the stromal cell:membranes were removed and all cells trypsin harvested.
Increased numbers of C1.92 were found bound to the V49 over the C54 transwells.

Figure 7. Expression of VCAM-1 and fibronectin protein following exposure to 100µM
VP-16. ELISA analysis was used to evaluate (a) mVCAM-1 and fibronectin protein on
S-10 after 24 and 48 hours VP-16 exposure and (b) mVCAM-1 and hVCAM-1 protein
levels of C54 and V49 following 48 hours of VP-16 treatment. While reductions of
mVCAM-1 were observed in each line ((a) S-10, (b) C54 and V49), no reductions of
fibronectin ((a) S-10) or hVCAM-1 ((b) V49) were found.

Figure 8. Expansion and survival of the stromal cell-dependent pro-B cell line C1.92 on
C54 or V49 in the absence of rIL-7. Stromal cell capacity to support C1.92 survival in
the absence of exogenous growth factors was enhanced when cocultured with hVCAM1+ cell line V49 as compared to C54. [ * - statistically significant from both (-)IL-7
groups (P=0.001 "viability" and P<0.001 "viable cell number" || **

-

statistically

significant from C54 (-)IL-7 (P=0.018 “viability”) || ^ - statistically significant from both ()IL-7 groups (P<0.001 "viability" and P<0.001 "viable cell number") || ^^ - statistically
significant from C54 (-)IL-7 ( P<0.001 “viability”)]
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Figure 1. Mammalian expression vector maps (β-galactosidase
and human VCAM-1)
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Table 1. Qualitative expression of β-galactosidase in vector control
cell lines (C3, C5, C17, C27, C43, C48, C54, C64, and C73)

Relative β -galactosidase expression:
S-10pTlacZ clones
C3
C5
C17
C27
C43
C48
C54
C64
C73

++
+++++
+++
+
++
+++
+++++
++++
++
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Figure 2. Human VCAM-1 (hVCAM-1) expression on selected
hVCAM-1+ and β-gal+ cell lines
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Figure 3. Murine VCAM-1 (mVCAM-1) expression on representative
cell lines, C54 and V49
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Figure 4. Human and murine VCAM-1 RNA expression in multiple
cell lines
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Figure 5. Expansion of the stromal cell-dependent pro-B cell line
C1.92 on C54 or V49
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Figure 6. Pro-B cell clone C1.92 chemotaxis and binding associated
with C54 and V49 stromal cell clones
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Figure 7. Expression of VCAM-1 and fibronectin protein following
exposure to 100µM VP-16
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Figure 8. Expansion and survival of the stromal cell-dependent pro-B
cell line C1.92 on C54 or V49 in the absence of rIL-7
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Chapter V

Discussion

153

The broad goal of this study was to evaluate how specific chemotherapeutic
drugs affect the bone marrow microenvironment and its ability to support
hematopoiesis. Hematological deficiencies following myelosuppressive chemotherapy
or irradiation predispose patients to opportunistic pathogens and increase patient
morbidity and mortality following bone marrow transplantation (BMT). Characterization
of microenvironment damage following chemotherapy may lead to new preparative
regimens that minimize bone marrow toxicity and support maximal hematopoietic
recovery.
This study established that topoisomerase II inhibitors VP-16 and doxorubicin
negatively impacted stromal cell SDF-1 protein production and contributed to functional
deficits in stromal cell chemotactic signals (Chapter II). In addition, VP-16 exposure
resulted in stromal cell molecular alterations that account for previous observations of
reduced stromal cell VCAM-1 protein (Chapter III).

Finally, established VCAM-1-

engineered stromal cell lines will allow us to further delineate the functional roles of
altered VCAM-1 expression on stromal cells following chemotherapeutic exposures
(Chapter IV).
Expression of stromal cell chemokines, adhesion molecules, and cytokines effect
the ability of the microenvironment to support hematopoiesis. Previous work in our
laboratory determined that human stromal cells exposed to VP-16 had reduced VCAM-1
protein (1). In addition, we observed that doxorubicin also disrupted stromal cell VCAM1 protein. In addition, VP-16 and doxorubicin reduced stromal cell SDF-1 production
(Chapter II).

Taken together, these observations support the premise that specific

chemotherapeutic agents may blunt hematopoietic reconstitution by disrupting factors
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that underlie progenitor cell chemotaxis to, or retention within, appropriate stromal cell
niches of the marrow microenvironment (Figure 1 a-b).
Our model is based on functional in vitro evaluations of stromal cell damage
following dose-escalated treatment with VP-16. Clinical treatment strategies commonly
include various cocktails of chemotherapeutic agents alone or in conjunction with total
body irradiation (2).

Because complexities of multi-drug interactions with biological

systems present challenges in defining precise damage to the bone marrow
microenvironment in vivo, we narrowed our focus to the impact of single
chemotherapeutic agents bone marrow stromal cells (3-11).

VCAM-1 and SDF-1

support critical hematopoietic functions in stem cell maintenance, establishment of bone
marrow hematopoiesis, B-cell development, hematopoietic cell bone marrow homing,
and hematopoietic bone marrow retention (7;12-17), and VP-16 suppressed expression
of these stromal cell proteins for extended periods of time (Chapter II and III) .
Hematopoietic cell chemotaxis to, and retention within, the bone marrow relies on
local and peripheral SDF-1 concentration gradients (16;18-25). We demonstrated that
two independent topoisomerase II inhibitors, VP-16 and doxorubicin, functionally
disrupted bone marrow stromal cell capacities to support efficient chemotaxis of
immature hematopoietic cells by reducing stromal cell SDF-1 protein production. While
a range of doses was tested for each drug, clinically relevant doses were chosen as the
focus of our investigation. The functional ability of stromal cells to support chemotaxis
of immature B-cells was markedly reduced by stromal cell exposure to either
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Figure 1. Model of hematopoietic delays associated with altered stromal cell function
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chemotherapeutic agent, consistent with the reduction of SDF-1 that was observed
(Chapter II).
VP-16 is of particular interest as it is tolerated by patients at escalated doses,
while doxorubicin use at high levels is limited by cardiac toxicities (26;27).

Both

topoisomerase II inhibitors decreased SDF-1 production by stromal cells, while cytosine
arabinoside (Ara-C) or 4-hydroxycyclophosphamide (4-HC; the primary active
metabolite of cyclophosphamide) treatment had no effect on SDF-1 levels.

These

observations suggested that reduction of stromal cell SDF-1 production may correlate
with mechanisms of specific drugs or classes of drugs such as topoisomerase II
inhibitors. These results may explain variable observations seen clinically in the ability
of exogenous growth factors to facilitate lymphopoietic recovery (28-30).
Sustained deficits in hematopoietic recovery were noted following high dose
chemotherapy and bone marrow transplantation in many studies (31-33). Consistent
with delayed hematopoietic recovery following chemotherapy exposure, we observed
sustained reductions of SDF-1 protein levels from chemotherapy treated stromal cells
(Chapter II).

This correlated with a functional impairment of chemotherapy treated

stromal cells to support chemotaxis in vitro as well (Chapter II). Minimizing disruption of
stromal cell production of SDF-1 following chemotherapy exposure would likely result in
enhanced homing of hematopoietic stem cells to the bone marrow and shortened
delays in hematopoietic recovery following bone marrow transplantation.
Previously, bone marrow stromal cells treated with VP-16 resulted in reduced
stromal cell capacity to support survival and proliferation of lymphoid and myeloid
progenitor cells. Diminished levels of VCAM-1 protein expression were also observed
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in that study (1). Because interaction of hematopoietic progenitor cells with VCAM-1 on
stromal cells has been shown to be important for development of B cell progenitors (3437), we investigated the potential mechanism by which VP-16 exposure results in
dysregulated VCAM-1 expression.
VP-16 exposure suppressed endogenous stromal cell VCAM-1 gene promoter
activity through changes in nuclear NF-κB profiles resulting in diminished VCAM-1 RNA
and protein.

Recovery of p65 and p50 nuclear levels to baseline following brief

exposure to VP-16 suggested an absence of permanent damage to stromal cells
following short-term treatment (Chapter III). In addition, restoration of VCAM-1 protein
following removal of drug occurred following a 24-hour VP-16 exposure but not following
72 hours (Chapter III). These observations suggested potential links between duration
of drug exposure and severity of damage that may be as critical to microenvironment
function as drug dose. Furthermore, the response of stromal cell NF-κB to specific
chemotherapeutic agents may provide insight into mechanisms that contribute to a
disrupted bone marrow microenvironment, and the delayed hematopoietic recovery that
is associated with specific chemotherapeutic agents.
Stromal cell lines that constitutively express human VCAM-1 protein may be
beneficial in restoration of bone marrow support of hematopoiesis following BMT (Figure
2).

Our engineered stromal cell lines sustained vector specific gene expression

following exposure to VP-16 and supported enhanced viability of pro-B cells in the
absence of exogenous IL-7 (Chapter IV). These stromal cell lines may prove useful
during bone marrow transplantation if stromal cells that over express VCAM-1 are coinfused with hematopoietic cells and engraft within the bone marrow (38-41).
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Figure 2. Corrective bone marrow environment following dose-escalated chemotherapy
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Constitutive VCAM-1 expressing stromal cells would maintain expression of VCAM-1,
even in microenvironments containing residual cytotoxic compounds, and potentially
restore and maintain baseline levels of B-lymphopoiesis (Figure 2).
Long-term engraftment of stromal cells has not been established. In fact, several
studies have suggested that stromal cells have finite (<2 years) life spans following
bone marrow engraftment (42;43). These studies suggest potential therapeutic uses of
engineered stromal cells in enhancement of short-term B-lymphopoiesis following bone
marrow transplantation with minimal long-term consequences.
As chemotherapy doses escalate to achieve maximal tumor cell death, stromal
cell damage is inevitable (12;33;44-47). Several recent studies have demonstrated that
co-infusion or replacement of damaged cells with healthy stromal cells in conjunction
with hematopoietic cells leads to enhanced hematopoietic recoveries following bone
marrow transplantation (38;39).

In the context of stromal cell replacement following

ablative chemotherapy, stromal cells engineered to express specific hematopoietic
growth factors or adhesion molecules may enhance stem cell maintenance and
engraftment if established in correct microenvironments. Additionally, healthy stromal
cells may enrich hematopoietic stem and progenitor cell homing, and restore robust Bcell development (Figure 2). As such, VCAM-1 engineered stromal cell lines may prove
useful in therapeutic procedures during high-dose chemotherapy treatment strategies.
Restoration of hematopoiesis is often clinically defined as recovery of absolute
numbers of neutrophils and platelets (2).
recovery is incomplete and misleading.

However, this definition of hematopoietic
Hematopoietic recovery also encompasses

restoration of B and T cell populations, bone marrow microenvironment cellularity, and
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functional competence of these cells. Several recent studies addressed the deficits of
information on damage sustained to the functional capacity of bone marrow following
ablative regiments of chemotherapy and irradiation (2;40;45;48;49). Unfortunately, our
understanding of the sustained damage and consequences of bone marrow
microenvironmental toxicity remain incomplete (48).
Although bone marrow stromal cells demonstrate high radioresistance due to
observed slow turnover rates in vivo (50;51), functional deficits of bone marrow stromal
cells in osteogenic potential, proliferative capacity, and hematopoietic support (1;45;4749) are now being reported. With the reported success of high-dose chemotherapy in
patients with various hematological and non-hematological cancers (52-54), it is
essential to better define bone marrow microenvironmental damage following
aggressive chemotherapy and bone marrow transplantation.

A fundamental

understanding of stromal cell damage is important for success in development of new
treatment strategies, enhanced drug design, and other measures that minimize bone
marrow microenvironment toxicity.
This study has focused on myelosupportive alterations of stromal cells following
chemotherapy exposure. Another common consequence of stromal cell damage is
dysregulation of bone mineral metabolism. Recent work has begun to characterize
mechanisms contributing to diminished bone mineral density (BMD) and osteoporosis in
patients following bone marrow transplantation (55;56). One group identified reduced
capacities of bone marrow stromal cells to differentiate into osteoblasts when evaluated
ex vivo from patients who had recently undergone bone marrow transplantation (57).

Other studies documented enhanced bone mineral absorption in conjunction with
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diminished bone formation in patients following bone marrow transplantation (58-60).
Although it is clear that altered stromal cell function contributes to these observations,
mechanisms of stromal cell damage leading to alterations in bone mineral metabolism
are poorly understood.
In conclusion, bone marrow stromal cells have been defined as a radioresistant
population (50;51), but it is clear that they sustain widespread molecular and functional
damage following preparative treatment regimens and bone marrow transplantation.
Diminished self-renewal, hematopoietic support, and multipotential differentiation are
three defined areas of stromal cell dysregulation following bone marrow transplantation.
The efficacy of cytotoxic treatment strategies must consider the long-term damage
sustained to bone marrow stromal cells, or alternatively, further progress in restoration
of the bone marrow microenvironment through stromal cell transplantation for must be
developed (61;62).
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